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ABSTRACT 
The metastatic process requires that tumour cells are capable of traversing 
various micro-environmental barriers, such as the basement membrane. There 
are various proteolytic mechanisms which could contribute to the process, 
plasminogen activation by tissue plasminogen activator (tPA) and urokinase 
plasminogen activator (uPA) is one such mechanism. Extensive reports in the 
literature (reviewed in the introduction) indicate that most tumour cells synthesize 
uPA and that it is this enzyme, particularly when receptor-bound, which plays a 
role in invasion. 
UCT-Mel 3 is a human malignant melanoma cell line which was established in our 
laboratory, and has been shown to be highly metastatic in the nude mouse. This 
cell line is typical of many melanomas in that it synthesizes only tPA and not uPA. 
In part 1 of this thesis I further investigated the plasminogen activator production 
by these cells (at the level of mRNA as well as activity) as well as expression of 
plasminogen activator inhibitor PAl-1 and receptors for tPA and uPA (uPAR). 
UCT-Mel 3 cells expressed uPAR although uPA was not detected. I also 
examined cells cultured from two metastatic deposits. Interestingly, the 
metastatic cells produced PAl-1 which was undetected in the parent cells. 
After confirming that UCT-Mel 3 do not express detectable levels of uPA, I 
attempted (in part 2) to determine whether tPA could play a comparable role to 
that of uPA in the invasive process. My strategy was to inhibit the expression of 
tPA via two different methods, namely the use of antisense RNA and ribozyme. I 
then hoped to isolate clones producing no tPA, which would have been injected 
into nude mice in order to assay for metastasis. Unfortunately neither of these 
methods proved to be successful in abrogating tPA expression. I was thus 
unable to achieve the ultimate aim of the project. However, during the course of 
the study a number of unforeseen problems arose. Firstly, the clonal variation 
within the cell population, and secondly, my inability to obtain antisense 
transfectants. I have speculated that a possible reason for the latter may be that 
the cells are in fact unable to grow in the absence of tPA. 
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LITERATURE REVIEW 
The Role of Plasminogen Activators in Invasion and Metastasis 
METASTASIS/INVASION 
Perhaps the most important difference between a benign and malignant tumour 
resides in the ability of the latter to invade normal tissues and to metastasize to 
distant sites throughout the body. It is this metastatic capability which makes 
cancer such a difficult disease to treat. 
The vascular metastatic process is thought to involve a number of steps (1, 2): 
1. Invasion of surrounding tissues by primary tumour cells. 
2. Angiogenesis: tumours induce their own supply of blood vessels to 
nourish the rapidly expanding mass. 
3. lntravasation: tumour cells infiltrate capillaries and enter the circulation. 
4. Embolus formation: interaction of tumour cells in the bloodstream with 
fibrin and platelets. 
4. Arrest: some of these malignant cells arrest in capillary beds at sites 
distant from the primary tumour. Arrest may result from obstruction of a 
narrow vessel or adhesion to the inner lining of the vessel. 
5. Extravasation: tumour cells penetrate the vessel walls and enter the 
su:-rounding tissues where they proliferate to form secondary tumours 
(metastases). 
Similar mechanisms, involving the lymphatics, are believed to be involved in 
spread to regional lymph nodes. 
Tumour metastasis is a rather inefficient process, with less than 0.1% of 
circulating cells ultimately surviving to produce a metastatic focus (3). To survive 
the passage from primary site to distal deposit they must avoid host defences and 
withstand mechanical turbulence in the circulation. Some form of protective 
covering is thus required (4). Procoagulants, liberated by tumour cells, activate 
plasma clotting factors so that the tumour embolus becomes enmeshed in a 
covering fibrin coat. Platelet deposition adds to the shielding and enlarges the 
embolus, so favouring terminal lodging and protection from the she&:- forces of 
blood flow. 
Site-specific metastasis 
Two theories exist to explain the sites of metastases. According to the "seed and 
so:!" hypothesis, tumour cells are predisposed to spread to particular tissues on 
th2 basis of a propitious interaction between the cells and the tissue in question 
(5). Others have argued that, although organ-specific metastasis does occur, this 
could be attributed to routes of blood flow away from the primary tumour (6). 
Thus tumour cells would arrest in the next downstream capillary bed from the 
primary site. It would now appear that these theories are not mutually exclusive. 
Site-specific factors may include growth factors, adhesion molecules and 
chemotactic molecules. 
Invasion 
The process of invasion is a recurrent theme in all considerations of metastasis. 
Invasiveness describes the ability of cells to cross such anatomical barriers as 
extracellular matrix, basement membranes and interstitial stroma. Apart from the 
role of invasion in tumour development, invasive behavior occurs normally during 
embryogenesis, trophoblast implantation, angiogenesis and extravasation of 
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leukocytes in inflammation and wound repair (7, 8). While the mechanisms of 
invasion are likely to be the same for normal and malignant cells, the difference 
lies in the regulation. Normal invasion stops when the stimulus is removed while 
malignant cells migrate relentlessly. 
Requirements for the tumour cell to traverse the basement membrane are firstly 
adhesion to basement membrane components via cell surface molecules, 
followed by localized degradation of basement membrane molecules and then 
migration into the zone of lysis. Continued invasion would take place by cyclical 
repetition of these three steps. 
Adhesion 
The importance of adhesion in the later stages of metastasis has been illustrated 
by studies with B16 mouse melanoma cells. Co-injection of B16 cells with the 
GRGDS peptide, responsible for fibronectin binding to its receptor, inhibited 
formation of lung colonies (9) and prolonged host survival (10). In addition, a 
number of studies have illustrated the importance of adhesion molecules in site-
specificity of colonization (11 ). Tumour cells with different organ-site preferences 
have been incubated in vitro with endothelial cells isolated from the cultured 
microvasculature of the various organs. In most cases the tumour cells adhered 
selectively to endothelial cells derived from their preferred metastatic site (12). 
Tumour cells may cause endothelial cells to retract, so allowing adherence to the 
exposed matrix. Similar experiments have indicated preference for adhesion to 
matrix from the metastatic organ (13). The expression of adhesion molecules on 
the surface of endothelial cells can be induced by cytokines (tumour necrosis 
factor, interleukin 1) which may be secreted by the tumour cells (14) and there is 
3 
evidence to indicate that the extracellular matrix (ECM) upon which endothelial 
cells reside influences the expression of organ specific adhesion molecules (15). 
Motility 
Active motility enhances metastatic potential and is a property of most metastatic 
tumour cells (16). Factors which are chemotactic for tumour cells include 
fragments of ECM molecules, such as fibronectin and laminin (17-19), which are 
produced by tumour-derived enzymes. 
PROTEASES IMPLICATED IN INVASION AND METASTASIS 
A number of proteases have been implicated in the invasive process. The 
extracellular matrix consists of collagens, glycoproteins (eg. fibronectin, laminin ), 
proteoglycans and glycosaminoglycans. ECM-degrading proteases produced by 
invading cells may be divided into three subtypes: 
1) metalloproteases, 
2) serine proteases and 
3) cysteine proteases. 
This review will be confined mostly to the plasminogen activators, however, there 
is also substantial evidence to suggest that the collagenases play an important 
role in invasion and metastasis. The metalloproteases include interstitial 
collagenase and type IV collagenase. These enzymes are secreted in a latent 
form and require activation by limited proteolysis - usually by serine proteases 
(20). They are inhibited by specific tissue inhibitors of metalloproteases (TIMPs). 
The best characterized serine proteases are the plasminogen activators. The 
PA's convert the zymogen plasminogen, a ubiquitous plasma protein, to plasmin 
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(21). Plasmin plays an important role in controlling hemostasis by degrading 
fibrin. It has a broad specificity and can degrade several ECM components, 
including fibronectin, laminin and the core protein of proteoglycans (22). In 
addition, plasmin may contribute indirectly to extracellular proteolysis by activating 
certain prometalloproteases (20). Two types of plasminogen activators exist, 
namely the urokinase type (uPA) and the tissue-type (tPA). Although there is 
about 40% structural homology, they have distinct origins and functions (7, 23). 
Tissue plasminogen activator (tPA) 
The tPA gene is located on chromosome 8 (24) and spans more than 30 kb. The 
sequence contains fourteen coding regions separated by thirteen intrans, and is 
transcribed into a 2.7 kb mRNA (25). Mature tPA is a single-chain glycoprotein of 
530 amino acids (70 kD) from which a 32 amino acid leader sequence has been 
removed prior to secretion (26). 
Fibrin/PAl-1 Binding Site 
Serfne Proteaae Domatn 
+ Cleavage sne 
The structure of tissue plasminogen activator 
The arrow indicates the cleavage site for the conversion of single chain-tPA to two 
chain-tPA 
(figure reproduced from ref. 137 ) 
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Cleavage of the Arg278_11e279 bond by plasmin, tissue kallikrein or factor Xa 
yields tc-tPA which comprises an A and B chain held together by a disulfide bond. 
tc-tPA is 10-50 times more active in the presence of fibrin. The catalytic site is 
located on the B chain and contains the His, Asp and Ser residues which are 
characteristic of the active site of all serine proteases (7). 
The A chain contains three domains, a cysteine rich "growth factor domain" 
(residues 54-87) with homology to epidermal growth factor, a domain resembling 
the "finger" domain of fibronectin, and the "kringle" domain. The latter contains 
two kringle structures related to those found in prothrombin, plasminogen and 
factor XII. tPA has a strong affinity for fibrin, imparted by lysine binding sites in the 
kringles. Because plasminogen also binds to fibrin, colocalization of tPA, 
plasminogen and fibrin results in a 60-fold decrease of the Michaelis constant for 
plasminogen activation (7). 
tPA is believed to be primarily involved in clot lysis during fibrinolysis. It is 
produced by, amongst others, vascular endothelial cells, with a normal plasma 
level of about 5 ng/ml, of which over 95% is bound to plasminogen activator 
inhibitor-1 (PAl-1). tPA has a short plasma half-life before being cleared by cells in 
the liver (23). 
tPA Receptor 
Cell surface associated tPA has been reported for a number of cell types 
including human umbilical vein endothelial cells (HUVEC) (27), human aortic 
endothelial cells (HAEC) (28), hepatoma cells (29, 30) and melanoma cells (31 ). 
However a single, well defined receptor such as that for uPA remains to be 
demonstrated. 
6 
Hajjar et al. identified two binding sites for tPA on HUVEC cells, namely a high 
affinity (~ = 28 pM) and low affinity (~ = 18 nM) (32). Later the same authors 
further characterized a dual plasminogen-tPA receptor in placental extract (33), 
which appears to be identical to the low affinity receptor above. The affinity of this 
40 kD receptor for tPA (~ =30 nM) is somewhat higher than for plasminogen 
(~ = 114-120 nM), in addition lysine binding sites appear to be involved only in the 
case of plasminogen. This evidence suggests that the receptor expressed on 
endothelial cells may juxtapose tPA and plasminogen, in such a way as to 
promote plasmin generation. 
Another study involving HUVEC cells provides evidence for two tPA binding sites 
(34). The high affinity binding site (~ not determined) was shown to be PAl-1, 
and binding required the active site of tPA, with subsequent inactivation. Binding 
to the low affinity site was independent of the catalytic site with a ~ of 170 nM. 
These results appear to conflict with those of Hajjar et al., although possibly the 
low affinity site (34) is equivalent to the tPA-plsg receptor and the PAl-1 site 
equivalent to the high affinity site described by Hajjar et al. HAEC express a single 
class of tPA receptors with~ of 1.2 nM (28), it is not clear how this receptor is 
related to the HUVEC receptors. 
In contrast to the endothelial cell receptors discussed above, tPA bound to 
hepatoma cells (29, 30) is rapidly internalized and degraded. These receptors are 
presumably involved in tPA clearance in the liver. 
It is clear from the extensive literature on the subject, that cell surface associated 
uPA plays a role in invasion of a variety cancer cell types (see 35 for review). A 
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notable exception however, is melanoma, since the majority of melanoma cell 
lines produce only tPA and not uPA (36, 37, 38). A melanoma tPA receptor would 
be of interest as it could provide an alternative mechanism for plasminogen 
activation at the cell surface. 
In a recent study, cell surface associated tPA was demonstrated in five tPA 
producing melanoma cell lines (31). Cell associated tPA was measured by 
assaying tPA activity in acid eluates of adherent cells, with the implication that tPA 
could be bound to either the matrix or the cells. Plasminogen activation on the 
cell surface was demonstrated, and this could be inhibited to anti-catalytic 
antibodies to tP A. Thus although this study provides some evidence for a 
melanoma tPA receptor, specific tPA binding to a defined receptor on melanoma 
cells remains to be demonstrated. 
Urokinase plasminogen activator (uPA) 
s1ng1e - two cna,n Calalyhc AA 
.... ... ... 
,,_....,._ Lys 15s·lle159 - H,s 204 - Ase 255 
Serine ProteaH Domatn 
• Cleavage Stle 
The structure of urokinase plasminogen activator 
The first arrow indicates the cleavage site for the conversion of HMW uPA to LMW 
uPA, with the release of the ATF (Lys 135-Lys 136). The second arrow indicates the 
cleavage site for the conversion of sc-uPA to tc-uPA (reproduced from ref. 137). 
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Urokinase-type PA was first isolated from urine (39, 40), from which its name is 
derived. uPA is secreted as a single chain zymogen of 54 kD (41-43). Digestion 
by plasmin or tissue kallikrein cleaves sc-uPA into A and B chains which remain 
attached by a disulfide bridge (44). As in the case of tPA, the B chain contains the 
catalytic site, and consequently the binding sites for the inhibitors PAl-1 and PAl-
2. 
Similarly to tPA, the A chain of uPA contains both growth factor and kringle 
domains. However, the single kringle domain of uPA has no lysine binding site 
and hence lacks affinity for fibrin. The functional significance of the growth factor 
domain is that it forms the binding site for the cellular receptor for uPA (uPAR) 
(45). Part of the A chain can be cleaved off, to form the amino terminal fragment 
(ATF), which contains the growth factor domain, and LMW uPA (33 kD). 
Other functions for uPA apart from plasminogen activation have been elucidated. 
uPA can directly activate procollagenases, independently of plasminogen (46). In 
addition, uPA has been shown to have a mitogenic effect upon certain cells in 
culture (47-51). The ATF is required to demonstrate stimulation, since LMW uPA 
shows no effect. However it remains controversial as to whether or not the intact 
active enzyme is required (52). Although the mechanism for this stimulatory effect 
of uPA remains unknown, it may involve signal transduction upon binding of the 
uPA to the receptor, as in the case of other ligand-receptor systems (eg. 53). 
Receptor phosphorylation is common to many signal transduction pathways that 
promote growth and differentiation, and although the uPAR itself is not 
phosphorylated upon binding uPA, recent evidence indicates that interaction of 
uPA with its receptor induces tyrosine phosphorylation of an associated 38 kD 
protein (54). 
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uPA receptor 
The cellular receptor for uPA has been well characterized by a number of authors 
(55-61). The uPAR is expressed as a single chain 55-60 kd glycoprotein (55, 56) 
and is linked to the cell surface via a glycosyl-phosphatidylinositol (GPI) anchor 
(60). The uPAR binds specifically to both forms of uPA with high affinity (58, 62). 
The number of receptors per cell varies and may be induced by various agents 
including phorbol 12-myristate 13-acetate (PMA) (63, 64). 
Binding of uPA to its receptor has a number of important effects. There are 
numerous low affinity cellular plasminogen binding sites (65) and the conversion 
of plasminogen to plasmin by sc-uPA is increased 20-fold when uPA and 
plasminogen are both localized on the cell surface (62, 65, 66). In addition the 
conversion of sc-uPA to tc-uPA by plasmin is increased 50-fold when it is receptor 
bound. Receptor bound tc-uPA converts plasminogen to plasmin at a greater 
rate (62). 
Inhibition by PAl-1 and PAl-2 is decreased by 40% after uPA has bound to its 
receptor (67, 68). Receptor-bound uPA has been shown to be localized at focal 
contacts of cells, thus facilitating proteolysis during cell movement (68, 69). uPA 
bound to the receptor remains on the cell surface for several hours, and is not 
internalized and degraded except when complexed with PAl-1 (58). 
uPA has been shown to be capable of cleaving its own receptor (70), generating a 
cell-associated form incapable of ligand binding. Binding of uPA to the receptor is 
not required, since LMW uPA is also capable of cleavage. This reaction may 
represent a further mechanism for regulation of plasminogen activation. 
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Regulation of plasminogen activators 
The expression of PA activity is controlled at three levels. 
1) gene transcription: Expression of PA is controlled at the transcriptional level by 
a number of agents, including tumour promoters, oncogenes and growth factors 
(70). 
2) proenzyme activation (as described above) 
3) inhibition by specific inhibitors (discussed below) 
Inhibitors: PAl-1 (endothelial type) is an approximately 50 kD glycoprotein which 
is produced by a variety of cell types and is also present in plasma (72). Two PAl-
1 mRNA species exist (2.3 and 3.2 kb) which, due to alternative polyadenylation, 
differ only in the length of the 3' untranslated region (73). PAl-1 is unstable when 
secreted and becomes latent, unless stabilized by binding to vitronectin in the 
ECM (74). Latent PAl-1 can be reactivated in vitro by treatment with denaturants, 
such as guanidine, urea and SOS. PAl-1 inhibits the two chain forms of tPA and 
uPA, rapidly forming 1 :1 molar complexes, however it has poor affinity for the 
single chain forms. 
Other PA inhibitors include PAl-2 (placental type) and protease nexin 1. PAl-2 
inhibits tc-uPA tenfold more efficiently than tc-tPA, and has little effect on the 
single chain forms (75). Protease nexin was originally purified from cultured 
fibroblasts and is an inhibitor of thrombin, plasmin, trypsin and uPA (76). 
11 
EVIDENCE FOR INVOLVEMENT OF PROTEASES IN METASTASIS 
There is a substantial body of evidence which suggests that proteases play a 
crucial role in invasion and metastasis of tumor cells (see 77-79 for reviews). 
Three lines of evidence supporting this view are discussed below: 
1. Proteases are Involved In normal tissue remodelling 
In order for tumour cells to invade and metastasize, they are required to breach 
micro-environmental barriers such as the basement membrane (BM). This 
disruption of the BM is one of the main criteria for assessing tumour malignancy. 
Proteases, including the PA's, are involved in normal physiological processes 
where tissue destruction and remodelling occurs (eg. angiogenesis, inflammation, 
trophoblast implantation and wound repair) (7, 8), thus it seems likely that they 
may play a similar role in cancer cell invasion. Increased expression of proteases 
is widely considered to be a property of malignant transformation (7). 
2. Correlation between protease activity and metastatic potential of 
various tumours 
Indirect evidence for the involvement of PA in tumour invasion and metastasis has 
been provided by numerous studies showing increased levels of proteases in 
malignant tissue compared to normal or benign tissue. Increased levels of uPA 
and PAl-1 in breast carcinoma as compared to benign levels has been associated 
with a higher relapse rate, whereas tPA appears to be a favorable prognostic 
marker (80-86). Increased uPA antigen has been reported in colon carcinoma as 
compared with normal tissue (87, 88). lmmunocytochemistry of primary and 
metastatic tumours of pulmonary adenocarcinoma showed higher frequency of 
uPA positive cells in metastatic lesions than in primary ones. In addition, the 
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prognostic markers for cancer, however they fail to provide direct evidence for the 
role of proteases in invasion and metastasis. 
Positive correlations between protease activity and invasive potential may also be 
observed in model cell lines. For example, sublines of 816 mouse melanoma 
cells are often used tor metastatic studies in the mouse. In two of these sublines, 
B16F10 which is highly metastatic; and B16F1 which seldom metastasizes to the 
lung, the levels of PA have been shown to correlate with this metastatic potential 
(90). 
In another study of this type, Quax et al. (91) examined five melanoma cell lines, 
all of which produced tPA and uPAR and only two produced uPA, were examined 
in vitro and in vivo. All five melanomas showed plasmin-dependent degradation of 
smooth muscle ECM, although the uPA-producing lines were more invasive. After 
subcutaneous injection into nude mice, all of the lines developed primary 
tumours. A correlation was shown between uPA and PAl-1 production and 
spontaneous metastasis in nude mice. However no correlation was shown 
between uPA and PAl-1 and lung colonization following intravenous inoculation, 
with all lines producing colonies with a frequency > 50%. This would indicate a 
critical role for uPA in intravasation. 
3. Experimental approaches using model systems 
Experiments designed to demonstrate a role for proteases in metastasis have 
been the focus of much interest in recent years. Most of these studies involve the 
manipulation of protease activity (via the use of protease inhibitors, antibodies, 
transfections etc.) using both in vitro and in vivo models for invasion/metastasis. 
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Experimental models available: 
In order to determine whether or not proteases are involved in the invasion of 
tumour cells, suitable in vitro and in vivo models are required. Models currently 
available for studying tumour invasion and metastasis include: 
Degradation of labelled ECM components (eg. laminin, fibronectin), metabolically 
labelled ECM from cultured cells and matrigel (reconstituted ECM). ECM 
component studies allow one to investigate degradation of individual substrates 
although this is far removed from the real situation. The higher complexity of 
matrigel and cultured ECM makes them realistic substrates, although it should be 
remembered that ECM composition varies among cell types and may be 
influenced in vivo by surrounding cells (77). 
Natural basement membranes (eg. human amniotic membrane, chorioallantoic 
membrane, bovine lens capsule) are often used for in vitro invasion studies. 
There is good correlation between invasion of the amniotic membrane and in vivo 
metastasis (92). Studies based on these models may be more relevant, however 
they tend to be technically difficult due to low basal invasion rates and poor 
reproducibility. 
In vivo assays are usually the models of choice; these include invasion of CAM 
and metastasis formation in the embryo lung and invasion and metastasis 
following subcutaneous injection or organ colonization following intravenous 
injection of athymic mice. 
Metastatic assays in the chick embryo are relatively inexpensive, sensitive and 
quantitative, but the composition of the chorioallantoic membrane (CAM) may 
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differ from the relevant human basement membrane. Spontaneous metastasis 
experiments in athymic mice are expensive, lengthy and microscopic metastases 
are difficult to quantitate. In addition, tumour to host size is usually much larger in 
experimental animals than in humans where undetectable tumours often 
metastasize (77). 
Enumeration of lung colonization after i.v. injection of athymic mice is useful as it 
enables investigation only of the later stages of metastasis, however the release of 
huge numbers of tumour cells into the circulation does not resemble the real 
situation where only very few cells enter the circulation. There is also a need for 
assays which measure involvement in only the earlier steps of metastasis (77). 
Clearly an ideal model for tumour invasion does not exist and thus a number of 
different approaches may be required to elucidate the role of proteases in 
invasion. 
In vitro studies 
Many of the recent in vitro studies have focused on the role of uPA and the uPAR 
in invasion and metastasis. Human colon carcinoma cell lines with varying uPA 
binding capabilities were used in ECM invasion studies by Hallas et al. (93). GEO 
colon carcinoma cells which express low levels of uPA and uPAR were poorly 
invasive in the matrigel assay. Their invasiveness did not increase after 
transfection with the human uPA gene and subsequent eight-fold increase in uPA 
secretion. In contrast, the HCT116 colon carcinoma cell line which has many 
uPAR molecules, all of which are saturated with uPA was highly invasive. This 
invasion was reduced by an antibody to the A chain of uPA which inhibits uPA-
uPAR binding. RKO colon carcinoma cells which have large numbers of 
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receptors which are not occupied due to low levels of endogenous uPA were 
poorly invasive, however pretreatment of the RKO cells with uPA resulted in 
increased receptor bound uPA and consequent increased invasion. Thus, for 
these colon carcinoma cells it appears that receptor bound uPA is essential for 
invasion. 
HT29 colon carcinoma cells express uPA receptors but no uPA. The cells were 
transfected with human uPA cDNA and the invasion of R22 smooth muscle ECM 
compared with that of the parental cells (94). Invasiveness was increased from 
below detection up to 15%. This increase in invasive ability was inhibited by anti-
catalytic antibodies to uPA, aprotinin and to a lesser degree by uPAR binding 
peptide and anti-uPAR antibodies. Thus, these results too indicate an important 
role for uPAR-mediated degradation. 
The work of Ossowski et al. confirms the importance of uPAR-mediated invasion 
(95, 96). In the first study (95), invasion of human tumor cells was reduced by the 
inhibition of tumor uPA. uPA was also added in order to saturate the receptors, 
with the result that invasion was increased. In a later study using the same model, 
mouse tumor cells were transfected with either human uPA or uPAR DNA. Co-
culturing and inoculation of both cell types onto the CAM resulted in a 4-fold 
stimulation of invasion, compared to either type alone. This again highlighted the 
importance of the uPAR in invasion, as well as illustrating that uPA can bind to the 
receptor in a paracrine fashion. 
It is possible that this scenario could also occur in vivo, with uPAR-bearing, 
malignant cells binding uPA from surrounding stromal cells. Further support for 
this theory comes from the work of Pyke et al. (97), who did in situ hybridization of 
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adenocarcinomas for uPA and uPAR mRNA. uPAR was detected in malignant 
cells at the periphery of tumours, while uPA mRNA was present only in stromal 
cells adjacent to the tumour. 
Quantitative proteolytic requirements: The amount of PA produced as well as 
the type may be important for invasion, as was shown by Tsuboi et al. (98). 
Bowes melanoma, HT1080 fibrosarcoma and Osmond hypernephroma cells were 
tested in the amnion invasion assay. Bowes which secretes large amounts of 
tPA, was poorly invasive, as was HT1080 which produces large amounts of uPA, 
however Osmond which produces low amounts of uPA, was highly invasive. 
Further elucidation was obtained by addition of antibodies to uPA, tPA and TIMP 
and plasmin inhibitors. Reduction of Bowes tPA activity by o-tPA antibody 
increased invasion and inhibition of HT1080 uPA by o-uPA antibodies had a 
similar effect. Invasion was also increased in Bowes and HT1080 cells by plasmin 
inhibitors. Invasion of Osmond cells was blocked by o:-uPA and plasmin inhibitor. 
The authors suggested that only a minimal level of plasminogen activation was 
required for invasion and levels greater than this could cause uncontrolled ECM 
degradation and interfere with matrix-cell contact. 
Concerted proteolytic activities: There is evidence that different proteases may 
act in concert during matrix degradation (99). The M24met human melanoma 
(highly metastatic) was tested for degradation of various matrix components and 
types. Inhibition of degradation by TIMP-2 and PAl-2 was tested. Results showed 
that uPA degraded primarily glycoproteins in the matrix and that this was a rate 
limiting step. Metalloprotease mediated degradation of collagens occurred only 
after removal of these protective glycoproteins. In addition they showed that uPA 
or plasmin was not required for activation of metalloproteases. 
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Another recent study suggests a dual role for uPA and collagenase in invasion 
(100). The HEp3 (hepatoma) cell line loses invasive ability with sequential 
passage in culture and the loss was correlated with a reduction of interstitial 
collagenase levels, although uPA levels remained high. In addition, six squamous 
carcinoma cell lines were tested for uPA levels and invasive ability on the CAM. 
All cell lines produced high levels of uPA, yet not all were invasive. Levels of 
collagenase were then investigated and a correlation was shown between 
interstitial collagenase and invasion. It would have been interesting if uPA 
inhibition studies had been included to test for absolute requirement of uPA. 
As can be seen from the majority of the literature, the picture which emerges is 
that of uPAR-bound uPA being largely responsible for invasion in a large variety of 
tumour cells. However, the case of human melanoma cells appears to be 
different since many highly metastatic melanoma cells produce only tPA and not 
uPA (36-38). 
A role for tPA in the invasion of melanoma was suggested by Meissauer et al. 
(101). Two melanoma cell lines producing tPA alone (MeWo) and tPA, uPA (cell 
assoc.) and PAl-1 (Mel Juso) were assayed for degradation of fibrin, matrigel and 
ECM in the presence of antibodies to uPA and tPA and aprotinin (101). Apro:inin 
decreased invasion by both cell lines, as did a-tPA i'l MeWo and a-uPA in Mel 
Juso, the ineffectiveness of a-tPA in inhibiting invasion of Mel Juso may be 
explained by free tPA being inhibited by PAl-1, whilst uPAR-bound uPA is 
protected. Invasion was only partly plasmin-dependent This suggests a role for 
tPA as well as uPA in in vitro invasion. However, in a later paper (102) the same 
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a~thors show that plasminogen is activated on the cell surface much more 
efficiently by uPAR-bound uPA (Mel Juso) than by secreted tPA (MeWo). 
In vivo studies 
Ossowski and Reich (103) showed in an early experiment using HEp3 cells in the 
chick embryo metastasis assay that an inhibitory antibody to uPA inhibited 
invasion and metastasis, but not growth of the primary tumour. Organ 
colonization, following intravenous injection of Hep3 cells was not inhibited by 
treatment with a-uPA. They were thus able to pinpoint the involvement of uPA to 
the stage of intravasation. These experiments were the first to illustrate the role of 
uPA in metastasis in an in vivo model. 
In a later study (104) Ossowski used labelled HEp3 cells in the CAM system to 
investigate the role of uPA in the individual steps of metastasis. Inoculation of 
HEp3 cells whose uPA activity was inhibited, resulted in 4-fold fewer tumor cells in 
the embryo organs. Since inhibition of uPA had no effect on either extravasation 
(shown by i.v. inoculation) of invasion through the CAM; there is indirect evidence 
that uPA is required for intravasation. 
Similar studies using HEp3 cells were extended to the nude mouse model (105). 
Mice were subcutaneously inoculated with HEp3 cells and then treated daily with 
injections of a-uPA antibody. Tumors larger than 1 g were excised and lungs 
were examined for metastases. Local invasion was inhibited compared to the 
controls, however metatasis was not reduced. The authors suggeted that this 
may reflect spread by a tumor protease-independent mechanism, arising from the 
pronounced granulocytosis caused by the HEp3 cells. 
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As mentioned previously, B16 mouse melanoma clones with varying metastatic 
potential have been useful models for studying metastasis. B 16F1 cells express 
uPAR but produce low amounts of uPA and are poorly metastatic. B16F,c cells 
express uPAR (106) and higher levels of uPA and are highly metastatic. B16F1 
cells were transfected with cDNA for human uPA (107). The uPA produced by 
transfected cells was not glycosylated and did not bind to the murine receptor. 
An increase of 200-1760% was noted in the lung colonization assay for a clone of 
uPA-transfected B16F1 cells as compared to untransfected controls. In addition 
spontaneous metastasis increased from 18% to 100% of mice injected. This 
indicates a role for non-surface associated uPA in extravasation, although one 
cannot draw any conclusions about involvement in the earlier stages. In the same 
study, B16F10 cells were transfected with antisense human uPA cDNA resulting in 
a 30% decrease in uPA activity. These transfectants exhibited a similar decrease 
in lung colonies compared to the control. Spontaneous metastasis was not 
tested. These results indicate that the difference in metastatic potential between 
B16F1 and B16F10 is due to the difference in levels of uPA produced and that 
secreted uPA plays a role in both intravasation and extravasation. 
In another study, B16F1o cells were pre-incubated with anticatalytic antibodies to 
uPA prior to i.v. inoculation of mice (106), with the result that colonization was 
inhibited by 60% compared to controls. Pre-incubation with plasmin increased 
lung colonization by 200-300%. In agreement with the B 16 study by Quax et al. 
(91 ), the implication is that uPA is involved in extravasation and the events which 
follow. The remaining colonizing capacity which was not inhibited by a-uPA may 
reflect a subpopulation of cells using different proteolytic mechanisms. This study 
illustrates one of the limitations of this assay, in that extremely variable results are 
obtained between experiments. These studies on 816 melanomas, although in 
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agreement with each other, contrast with those of Ossowski et al. which implicate 
uPA in intravasation only. 
Both uPA and tPA were implicated in invasion and extravasation by Axelrod et al. 
(108). Expression of PA's transfected into H-ras-transformed NIH 3T3 cells 
resulted in increased invasion of ECM and higher incidence of lung colonization 
after i.v. injection of mice. The role of PA's was corroborated by inhibition of 
invasion and colonization by a-uPA and a-tPA antibodies. 
These numerous reports do seem to indicate a role, primarily for receptor-bound 
uPA and possibly less for tPA, in invasion and metastasis of a wide range of 
different cancer cell types. Disparity between different reports may be due in part 
to the complexity of the metastatic process, also to the range of cell types 
studied, each of which may employ different proteolytic mechanisms for invasion. 
For example the two independent studies using 816 melanoma are in agreement, 
although the findings are in contrast to other studies using different cells. In 
addition participation of more than one proteolytic system may be required, as 
shown in (99). Another factor to consider, especially for correlative studies is the 
heterogeneity of tumour populations, and results obtained for the parental 
population may not apply to the small fraction of metastatic cells. 
When considering in vivo studies, it is possible that the spectrum of proteases 
released by the tumour cells when in the host may be different to in vitro due to 
interactions with host factors. Several observations indicate that paracrine or 
autocrine growth factors, as well as tumour-host interactions, can modulate the 
expression of proteases involved in tumour invasion and metastasis (109-111 ). 
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Some of the more important points to emerge from these studies may be 
summarized as follows: 
• Invasion is most effective when proteolysis is focused on the cell surface, 
rather than in the soluble phase (eg. 93). 
• PA's and metalloproteases appear to act in concert, forming a cascade of 
proteolysis (eg. 99, 100) 
• Indiscriminate proteolysis does not necessarily favour invasion (eg. 98), 
rather fine modulation is required, indicating a role for the inhibitors (eg. 
PAl-1, TIMP) 
R6cent evidence indicates a further role for proteases, particularly the PA's, in the 
modulation of tumour angiogenesis by: 
1. The release of matrix-associated basic fibroblast growth factor (bFGF) into 
the soluble phase. 
2. The activation of latent transforming growth factor-p (TGF-P). 
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Both of these factors are potent inducers of angiogenesis. In contrast to the 
process of tumour invasion, however, this proteolysis is finely controlled. Plasmin 
has been shown to release bFGF from the matrix (112), which stimulates PA and 
collagenase expression by vascular endothelial cells. This process is balanced by 
the effect of TGF-13, which down regulates protease expression and stimulates 
production of inhibitors (77). Once the active TGF-P is depleted, the production of 
proteases increases. Thus, the process of angiogenesis results from a series of 
cyclical phases of proteolysis and inhibition thereof. 
The question of whether fibrinolysis favours or inhibits tumour dissemination is an 
ongoing one. On the one hand proteolysis, particularly plasminogen activation is 
clearly important for intra- and extravasation. On the other, deposition of fibrin on 
the tumour embolus is thought to prevent destruction and favour lodgement, and 
there is evidence for involvement of PAl-1. Most likely a delicate balance of 
coagulation and fibrinolysis is involved. 
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PART1 
Expression of plasminogen activators, uPAR and PAl-1 in UCT-Mel 3 
cells 
Introduction 
Most human melanoma cell lines are known to release only tPA enzyme activity 
and no uPA activity (36-38). UCT-Mel 3 is no exception to this general rule. Hoal 
et al (36), using high affinity antibodies to tPA and uPA showed that all enzyme 
activity could be abolished by the former and none by the latter. Similarly, 
electrophoretic analysis with subsequent zymography and immunochemical 
inactivation has consistently shown that UCT-Mel 3 cells release only tPA and no 
detectable uPA. 
A growing body of opinion has come to suggest that uPA, bound in a functional 
state to its cell-surface receptor, plays a major role in the metastatic process (35). 
Indeed, Quax et al. (91) have produced data to indicate that only melanoma cells 
that released uPA were metastatic; tPA alone was insufficient to serve this 
process. Since UCT-Mel 3-derived tumors are consistently invasive and 
metastatic in the nude mouse and since the previous studies I have referred to 
failed to demonstrate uPA release by UCT-Mel 3 cultures, I felt it would be of 
interest to document this negative association more conclusively. I thus repeated 
experiments to define the nature of the PA released by UCT-Mel 3 cells. The 
absence of uPA release would thus tend to contradict the view that uPA was 
essential. 
It should, however, be remembered that, like most cultured melanoma cells, UCT-
Mel 3 cells could be expected to be clonally unstable. It was conceivable, 
therefore, that within the primary tumor, mutants might arise that would express 
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uPA and that it was these that invaded and metastasized. For them to do so, they 
would, according to current theory, require uPA receptor. Furthermore, their 
invasive and metastatic potential would be enhanced if they failed to release the 
potent PA inhibitor, PAl-1. I therefore examined metastatic deposits for uPA 
release and both metastases and the parent line for evidence of uPA receptor and 
PAl-1 synthesis 
Despite the fact that cultured melanoma cells and other malignant cell lines are 
known to differ qualitatively in their patterns of PA release (113) few attempts have 
been made to explain this difference, and little has been done to clarify the 
possible role of plasminogen activator inhibitors in determining the spectrum of 
proteases released by melanoma cells. This information was clearly of relevance 
to the theme of this thesis, so I undertook in addition, a series of experiments that 
were designed to provide an answer to the following question: Does the lack of 
uPA reflect a change in transcription, translation or a more profound change in 
the genome? 
If it should prove to be the case that the relative release of uPA and tPA showed a 
consistent pattern in melanoma cells, and moreover, if this pattern could be 
consistently explained by a common genetic mechanism, this would constitute an 
important descriptive contribution to our knowledge of a serious malignant 
disorder. 
In this chapter I describe the results of the experiments in which I addressed 
some of these questions. 
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Materials and Methods 
Antibody purification 
Polyclonal sheep antibodies that specifically inhibited either uPA or tPA were 
obtained from animals that had been immunized with preparations that were 
enzymatically pure (114). The immune sheep serum was purified by caprylic acid 
precipitation (115) as described (A.15). 
Fibrin plate assay for PA activity 
Serum-free conditioned medium from the UCT-Mel 3 cell line was tested in this 
assay as described in the appendix (A.7). The PA type was determined by 
incubating samples with inhibitory antibodies to uPA and tPA before assaying. 
Electrophoretic and zymographic analysis (95, with modification) 
Conditioned media and cell lysates were electrophoresed in 12% polyacrylamide 
gels alongside known tPA (20 µI Bowes conditioned medium) and uPA (1.25 
mU/ml) standards. Electrophoretically resolved bands of plasminogen activator 
activity were detected by washing the gels in detergent (to remove SDS) and then 
overlaying them with a layer of agarose containing casein and plasminogen 
(A.14). lmmunochemical identification of PA type was achieved by incorporating 
either a-tPA or a-uPA antibodies into duplicate overlays. 
RNA Extraction and Northern Blot analysis 
Cells growing as adherent monolayers were released with trypsin and their RNA 
was extracted using the one step Guanidinium Thiocyanate procedure (A.8). As 
a positive control for detecting mRNA transcripts for uPA, uPAR and PAl-1, I used 
RNA from the breast fibrosarcoma cell line, HT1080 (116). A probe for .B-Actin was 
hybridized to stripped blots to control for equal loading of lanes (117). 
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The RNA was electrophoresed in a formaldehyde/agarose gel (A.9) and the gel 
was treated and blotted according to the standard procedure described in the 
appendix (A.10) 
cDNA clones of the tPA, uPA, PAl-1, uPAR and .B-actin genes were used as 
probes (table 1.1). The fragments were purified by electrophoresis in low melting 
point agarose gels (A.11 ). Approximately 50 ng of each probe was random prime 
labelled with 50 µCi of a-32P dCTP. 
Table 1.1 Details of cDNA probes 
cDNA probe(l) plasmict< 2 ) enzyme digest< 3 ) 
uPA pSP64RUK EcoRI+HindIII 
tPA pW349F BglII 
PAI-1 PAI-1/pGEM3 EcoRI 
uPAR uPAR/pEMBL BamHI 
b-actin pHFbA-1 BamHI 
(1) sequence coded by cDNA 
(2) name of plasmid from which cDNA insert was excised 
(3) restriction enzyme/s used to excise insert 
(4) size of insert in base pairs 
size< 4 ) ref. 
600 bp 118 
2000 bp 119 
2944 bp 120 
660 bp 55 
1900 bp 117 
Blots were pre hybridized for 2 hr at 42°C before adding the freshly denatured, 
labelled probe. After hybridizing overnight the blots were washed twice in 2x SSC, 
0.1 % SDS for 15 min at room temperature and twice in 0.1 x SSC, 0.1 % SOS for 15 
min at 420C. Damp blots were sealed in plastic and exposed to x-ray film. 
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Culture of metastases 
Metastases were dissected from nude mice bearing UCT-Mel 3 derived 
subcutaneous primary tumours (121 ). The metastatic fragments were minced 
and dissociated by stirring with 0.25% Trypsin. The cell suspension was 
centrifuged and the cell pellet plated in RPMI containing 10% FCS (RP10). 
Adherent cells were serially passaged 4 times to yield pure cultures of metastatic 
human melanoma cells. Chromosome spreads of the metastatic cells were 
prepared (A.21) and examined in order to confirm their human origin. 
Measurement of PA in cultured metastases 
Both metastatic and parent UCT-Mel 3 cells were plated, in triplicate; at densities 
of 105, 2 x 105 and 106 cells/60 mm dish. Conditioned media were collected as 
described (A. 18) and assayed in the fibrin plate assay for PA activity. 
Southern blot analysis 
Genomic DNA analysis: Genomic DNA was isolated as described (A.12) and 
digested with EcoRI and Hindlll. 10 µg/lane of each digest was electrophoresed 
overnight on a 1 % agarose gel and the gel was treated and blotted as described 
(A.13). Blots were prehybridized at 68°C for 2 hr and then hybridized to the 
freshly denatured labelled probe overnight. They were then washed twice in 2x 
SSC, 0.1 % SOS for 15 min at room temperature and then twice in 0.1 x SSC, 0.1 % 
SOS at 68°C for 15 min. Damp membranes were sealed in plastic wrap and 
exposed to x-ray film. 
PAl-1 ELISA 
Conditioned media collected from UCT-Mel 3 cells and cells cultured from 
metastatic deposits were concentrated 10-fold using a centricon 
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microconcentator (Amicon) and then tested for the presence of PAl-1 antigen with 
an ELISA kit (American Diagnostica). 
Binding studies to demonstrate uPAR 
It is known that residues 3-135 of uPA (the amino terminal fragment; ATF) 
contains the binding site for the cell-surface uPA receptor (44). ATF, (a kind gift 
from Jack Henkin, Abbott Laboratories, Illinois) was labelled and used as a ligand 
to quantitate and characterize cell-surface uPAR. 
Receptors were stripped of uPA by acid treatment before performing all binding 
experiments (A.32). ATF (10 µg) was iodinated by the lodogen method (see A.20) 
using 250 µCi of 12s1 (50 µM). Two procedures were used to check the integrity of 
the labelled product. In the first, 0.4 pmoles of 1251-ATF were electrophoresed on 
a 12% SOS polyacrylamide gel, the gel was dried and then autoradiographed 
overnight to give the result shown in fig. 1.1. A single radioactive band, with a Mr 
appropriate for ATF was observed. By this criterion, therefore, the labelled ATF 
was physically intact. 
In the second procedure, the functional integrity of the labelled peptide was 
assessed by quantitating the amount of radioactivity that was bound by a 
saturating concentration of cells that are known to express uPAR. In this assay a 
fixed concentration of labelled ATF (1 nM) was incubated for 2 hr at 4°C with 
various numbers (1.3 x 105-106) of U937 cells suspended in 200 µI of H EPES 
buffered RPMI containing 0.5% BSA. The cell suspensions were then carefully 
layered onto 500 µI of FCS in a microfuge tube and centrifuged (400 g, 4°C) to 
separate cell-bound radioactivity (in the pellet) from free 12s1-ATF (in the 
supernatant above the FCS layer). The supernatant was aspirated and bound 
ligand was measured by counting the tubes in a 1-counter. 
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The reciprocal of the bound radioactivity was plotted as a function of the 
reciprocal of the cell number to yield the plot shown in fig. 1.2. Extrapolation to 
the ordinate axis (corresponding to an infinite cell concentration) showed that 
25% (declining with storage of the ATF) was functionally intact in the sense that it 
was capable of binding to the uPA receptor. Thus, for all subsequent binding 
experiments the concentration of labelled ATF added (b) was taken to represent 
0.25 x b that was capable of binding to uPAR. 
Figure 1.1 
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SDS PAGE with subsequent autoradiography of 1251-labelled ATF 
ATF was iodinated using the iodogen method and then 0.4 pmoles were 
electrophoresed on a 12% polyacrylamide gel. The gel was dried and 
autoradiographed overnight. The mobilities of molecular weight standards are 
indicated, from which the size of the labelled ATF was calculated to be 
approximately 14 kD. 
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Figure 1.2 
Double reciprocal plot of ATF binding to U937 cells 
1 nM 1251-labelled ATF was incubated with various numbers of U937 cells for 2 hr 
at 4°C. Unbound radioactivity was removed by spinning cells through a cushion 
of FCS, and the reciprocal of bound counts per min were plotted as a function of 
the reciprocal of cell number. Extrapolation to the ordinate axis showed that 7151 
cpm of the total 28755 cpm added were able to bind to an infinite concentration of 
cells, corresponding to 25% of functionally active 1251-ATF. 
Regression parametersfory=rnx+c: m=0.207, c=1.398, r=0.992 
Binding of 12s1-labelled ATF to U937 and UCT-Mel 3 cells was measured 
essentially as described above, save for the obvious fact that, in these 
experiments, the number of cells was kept constant (106 cells/200 µI) and the 
amount of ATF present was varied. In each of the first series of binding assays a 
constant amount of radioactivity (0.25 nM of functional 12s1-ATF) was diluted with 
different amounts of non-radioactive ATF in order to compete for the binding of 
1251-ATF. 
In the second series of experiments planned to generate Scatchard plots, 
doubling dilutions of (10 nM) functionally intact radioactive ATF (measured as 
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above) were added to U937 or UCT-Mel 3 cells in the absence (specific binding) 
or presence (non-specific binding) of a 100-fold excess of non-radioactive ATF. 
Tubes were incubated and processed as described to give values for bound and 
free ATF that were used for the analysis. 
Results 
Plasminogen activator synthesis by UCT-Mel 3 cells 
Plasminogen activator activity released by UCT-Mel 3 cells, and measured as the 
plasminogen-dependent release of 12s1-labelled fibrin, was inhibited by anti-tPA 
antibody but not by anti-uPA antibody (fig. 1.3). 
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Figure 1.3 
Antibody titration of UCT-Mel 3 harvest fluid in the 1251-fibrin plate assay 
Neat UCT-Mel 3 (1 OS cells/60 mm dish) harvest fluid was incubated with an equal 
volume of buffer or serial dilutlons of a-tPA or a-uPA polyclonal antibodies and 
incubated at 4°C for 1 hr. 80 µJ of each sample was then assayed in the 1251-fibrin 
plate assay as described (A.7), results were plotted as% of control (no antibody 
added) as a function of antibody concentration. 
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Zymography of electrophoresed plasminogen activator synthesized by UCT-Mel 3 
cells showed that, by the criterion of size (main band of caseinolysis at 70 kD) and 
immunochemical inhibition (fig. 1.4), these were all of tPA type; no detectable uPA 
activity was observed. 
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Figure 1.4 
SDS PAGE and zymography of UCT-Mel 3 cell lysate and conditioned 
medium. Conditioned medium (20 µI collected from 1 OS cells/60 mm dish) and 
cell lysate (20 µI of 1()6 cells/ml) were electrophoresed on a 12% polyacrylamide 
gel. The gel was washed in 2.5% Triton-X 100 for one hr and the resolved enzyme 
bands were detected by incubation on an indicator agar layer containing casein 
and plasminogen. Lane 1, uPA standard (1.25 mU/ml), lane 2, tPA standard (20 µI 
Bowes conditioned medium), lanes 3 and 5, UCT-Mel 3 conditioned medium, 
lanes 4 and 6, UCT-Mel 3 cell lysate. Panel A: standard overlay. Panel B: overlay 
incorporating a-tPA antibody 
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Electrophoresis and northern blotting of mRNA isolated from UCT-Mel 3 cells 
showed the definite, albeit faint, presence of tPA message. Despite prolonged 
autoradiography of the blots no uPA message was observed. The RNA isolated 
from HT1080 cells showed prominent bands that hybridized with probes for tPA 
(2700 bases) and uPA (2500 bases). These results are presented in fig. 1.5. 
UCT-Mel 3 cells thus transcribed and translated active tPA. No uPA mRNA or 
enzyme activity was detected using the above methods. 
tPA uPA PAl-1 
28S ... 
18S ... 
2 1 2 1 2 
p-actin 
Figure 1.5 
Northern Blot analysis of tPA, uPA and PAl-1 gene expression in UCT-Mel 3 
and HT1 oso cells 
Total RNA was isolated from UCT-Mel 3 (lane 1) and HT1080 cells (lane 2) and 20 
µg/lane was electrophoresed on a 1 % agarose-formaldehyde gel. The gel was 
blotted as described, and hybridized with 32P-labelled cDNA probes for tPA, uPA 
and PAl-1. Blots were washed and autoradiographed for 7 days. The blots were 
then stripped and rehybridized with a probe for .B-actin (lower panels). 
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Analysis of cells isolated from metastatic deposits in the adrenal and lung similarly 
showed only tPA activity and tPA mRNA (fig. 1.6). No evidence of uPA 
transcription or synthesis was found. However I am unable to exclude the 
existence of unstable uPA transcripts. It is of interest to note that the signal for 
tPA message in the northern blots of the metastatic cells was more intense than 
that of the parent cell line. 
tPA uPA 
28S~ 
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1 2 3 4 1 2 3 4 
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Figure 1.6 
Northern Blot analysis of tPA and uPA gene expression in UCT-Mel 3 adrenal and lung 
metastatic deposits 
Total RNA was isolated from cultured adrenal (lane 3) and lung (lane 4) metastatic deposits 
after the fourth passage. 20 µg/lane was electrophoresed, together with parental UCT-Mel 3 
(lane 1) RNA for comparison and HT1080 RNA (lane 2) as positive control, on a 1 % agarose-
formaldehyde gel. The gel was treated and blotted as described and hybridized with 32p_ 
labelled cDNA probes for tPA and uPA. The blots were washed and autoradiographed for 1 o 
days and then stripped and rehybridized with a ,8-actin probe (lower panels). 
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This did not correspond with the level of tPA released by the two cell cultures, as 
measured in the fibrin plate activity assay. Parental cells and metastatic cells 
released similar amounts of PA activity when corrected for a cell density of 5x105 
cells/60 mm dish (tabie 1.2). The amount of PA/cell released by UCT-Mel 3 
decreased with increasing cell density. In order to obtain a linear relationship, 
results were converted to PA units/106 cells/24 hr, and plotted against cell 
number on log scales. 
Table 1.2 Levels of PA release by UCT-Mel 3 parent and metastatic cells. 
CELL TYPE PA ( l) REGRESSION PARAMETERS (2) 
M C r 
PARENT 2.359 -0.464 ± 0.116 3.013 ± 0.673 0. 917 
AM 2.104 -0.372 ± 0.049 2.443 ± 0.276 0.967 
LM 2.827 -0.662 ± 0.038 4.224 ± 0.220 0.993 
t1) PA release calculated from regression for a cell density of 5x10S cells/60 mm dish 
(2) Regression parameters g:ven for the equation: 
log(y) = m.log(x) +c 
y= PA release/HP cells/24 hr 
x = cells/60 mm dish 
r = correlation coefficient 
PAl-1 synthesis by UCT-Mel 3 cells 
Neither ELISA analysis for PAl-1 protein nor northern blot analysis for PAl-1 
mRNA (fig. 1.5) provided evidence for the synthesis of this inhibitor by UCT-Mel 3 
parent cells. Simultaneous analysis of HT1080 cell mRNA showed prominent 
bands (approximately 2300 bases and 3200 bases) that hybridized with the PAl-1 
probe (fig. 1.5). It was of interest to note that the metastatic cells isolated from the 
adrenal deposit contained a small amount of PAl-1 message whose presence 
could be demonstrated in two separate northern blot experiments, the result from 
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one of these is shown in fig. 1.7. This correlated with the detectable release of 
PAl-1 by the culture of adrenal metastatic UCT-Mel 3 cells (table 1.3), as 
measured by PAl-1 ELISA. Cells cultured from the lung metastatic deposit also 
secreted detectable levels of PAl-1 protein, although the level was lower. 
PAl-1 
28S ..,. 
1as .... 
1 2 3 4 
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Figure 1.7 
Northern blot analysis of PAl-1 gene expression In UCT-Mel 3 adrenal and 
lung metastatic deposits 
Total RNA isolated from cultured adrenal Oane 3) and lung Oane 4) metastatic 
deposits after the fourth passage. The RNA was electrophoresed (20 µg/lane) 
together with that of UCT-Mel 3 parental Oane 1) and HT1080 Oane 2) on a 1 % 
agarose-forrnaldehyde gel. The gel was treated and blotted as described and 
then hybridized with a 32P-labelled PAl-1 cDNA probe. The blot was washed, 
autoradiographed for 14 days and then stripped and rehybridized with a fi-actin 
probe. The results shown are representative of two separate experiments. 
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Table 1.3 PAl-1 levels in concentrated (10-fold) conditioned media from 
UCT-Mel 3, adrenal and lung metastatic cells, as measured by ELISA. 
cell type PAI-1 (ng/ml) 
parental UCT-Mel 3 <P ( 1) 
adrenal met. 3.31 
lung met. 0.56 
(1) not detectable 
Synthesis of uPA receptor by UCT-Mel 3 cells 
Northern blot analysis of RNA isolated from UCT-Mel 3 cells showed the weak 
(relative to HT1080) but none the less definite and consistent presence of a band 
that hybridized with the uPAR probe (fig. 1.8). Interestingly the adrenal metastatic 
cells express higher levels of mRNA for uPAR than do the parent UCT-Mel 3 cells 
or the lung metastatic cells (fig. 1.9). 
Binding studies, using radio labelled ATF as ligand and U937 cells as a positive 
control (64), were therefore undertaken to identify functional uPA receptor on 
UCT-Mel 3 cells. Initially, specific binding of 12s1-ATF was demonstrated by 
competing out binding of labelled ATF with increasing concentrations of unlabeled 
ATF (fig. 1.10). 
For Scatchard analysis, increasing amounts of labelled ATF were added in the 
presence of an excess of unlabeled ATF (data shown in tables 1.4 and 1.5). Both 
U937 cells and UCT-Mel 3 cells showed saturable binding of ATF (fig. 1.11). 
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uPAR 
28S"' 
1 2 
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Figure 1.8 
Northern blot analysis of uPAR gene expression in UCT-Mel 3 and HT1080 
cells 
Total RNA isolated from UCT-Mel 3 Oane 1) and HT1080 Oane 2) cells was 
electrophoresed on a 1% agarose-formaldehyde gel (20 µg/lane). The gel was 
treated and blotted as described and then hybridized with a 32P-labelled cDNA 
probe for uPAR. The blot was washed, autoradiographed for 10 days and then 
stripped and rehybridized with a '9-actin probe Oower panels). 
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Figure 1.9 
Northern blot analysis of uPAR gene expression in UCT-Mel 3 adrenal and 
lung metastatic deposits 
Total RNA was isolated from cultured UCT-Mel 3 adrenal Oane 3) and lung Oane 4) 
metastatic deposits after the fourth passage. 20 µg of total RNA was 
electrophoresed together with RNA from parental Oane 1) and HT1080 cells (lane 
2) on a 1 % agarose-formaldehyde gel. The gel was treated and blotted onto 
Hybond-N as described and then hybridized with a 32p-tabelled uPAR cDNA 
probe. The blot was washed, autoradiographed for 10 days and then stripped and 
rehybridized with a ,8-actin probe Oower panels). 
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Binding of 1251-labelled ATF to U937 and UCT-Mel 3 cells in the presence of 
increasing concentrations of unlabelled ATF 
A fixed concentration of functionally active 1251-labelled ATF (0.25 nM) was 
incubated with 1D6 U937 (A) or UCT-Mel 3 cells (B) in the presence of increasing 
concentrations of unlabelled ATF. Incubations were performed in a volume of 200 
µI at 4°C for 2 hr. The concentration of labelled ATF bound is plotted as a function 
of the concentration of unlabelled ATF added. 
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Table 1.4 Scatchard analysis of data from binding of 1251-ATF to U937 cells 
ATF (~~ bound< 2 ) bound< 3 ) free< 4 ) b/f 
added (cpm) (nM) (nM) 
10.000 14771 0.394 9.606 0.398 
5.000 13044 0.348 4.652 0.726 
2.500 12775 0.341 2.159 1. 522 
1. 250 9802 0.262 0.988 2.554 
0.625 6534 0.175 0.450 3.544 
0.313 3474 0.093 0.220 3.843 
*o.156 1731 0.046 0.110 3.857 
*o.078 965 0.026 0.052 4.401 
*0.039 515 0.014 0.025 4.762 
*0.020 223 0.006 0.014 3.951 
*0.010 191 0.005 0.005 9.259 
*0.005 93 0.003 0.002 8.701 
Table 1.5 Scatchard analysis of data from binding of 1251-ATF to UCT-Mel 3 
cells 
ATF (ri~ bound< 2 > bound< 3 > free< 4 > b/f 
added 1 (cpm) (nM) (nM) 
¥10.000 16234 0.434 9.566 0.044 
(1) 
(2) 
(3) 
(4) 
* 
5.000 5064 0.135 4.865 0.027 
2.500 5598 0.150 2.350 0.061 
1. 250 5342 0.143 1.107 0.124 
0.625 3845 0.103 0.522 0.182 
0.313 2449 0.065 0.248 0.243 
0.156 1189 0.032 0.124 0.237 
*o.078 644 0.017 0.061 0.256 
*0.039 376 0.010 0.029 0.309 
*0.019 203 0.005 0.014 0.348 
*0.010 128 0.003 0.007 0.479 
*0.005 77 0.002 0.003 0.625 
concentration of functionally active 1251-ATF added 
cpm bound after subtracting non-specific control cpm (12% of cpm added) bound in the 
presence of 1 µM unlabeled ATF 
bound cpm converted to bound nM 
concentration of free ATF, obtained by subtracting (2) from (1) 
data obtained at low ligand concentrations were not included for scatchard analysis 
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Figure 1.11 
Binding of labelled ATF to U937 and UCT-Mel 3 cells 
Increasing amounts of labelled ATF were added to 10s cells and incubated on ice 
for 2 hr. Cells were then spun through a layer of FCS and the cell bound 
radioactivity in the pellet counted. Non-specific binding was determined in the 
presence of an excess of unlabelled ATF and subtracted from the total counts. 
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Figure 1.12 
Scatchard analysis of 1251-labelled ATF binding to U937 and UCT-Mel 3 cells 
(data from table 1.4 and 1.5) 
Increasing concentrations of 1251-labelled ATF were incubated with 106 U937 or 
UCT-Mel 3 cells at 4°C for 2 hr. Duplicate tubes containing an excess of 
unlabelled ATF (1 µM) were included for calculation of non-specific binding. 
The i<d (inverse of the slope) was calculated to be 0.83 nM for U937 cells and 0.59 
nM for UCT-Mel 3 cells. The x-axis intercept representing the number of sites is 
0.442 nM (53 200 sites/cell) for U937 cells and 0.19 nM (22 800 sites/cell) for 
UCT-Mel 3 cells. 
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Scatchard analysis of U937 binding showed the presence of a single receptor 
with a dissociation constant of 0.83 nM and present at a density of 5 x 1 Q4 binding 
sites per cell (fig. 1.12A). UCT Mel 3 cells appeared to express a similar receptor 
with a K:1 of 0.59 nM present at a density of 20 x 103/cell (fig. 1.12B). However at 
ligand concentrations greater than 5 nM, there appeared to be & sharp increase in 
binding to UCT-Mel 3 cells (table 1.5¥). Although there was insufficient data for 
scatchard analysis of this putative second class of receptor, it appeared to be of 
low affinity and high density. 
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Southern blot analysis of UCT-Mel 3 cell DNA for the presence of uPA, PAl-
1, uPAR and tPA genes 
Digests of UCT-Mel 3 DNA were electrophoresed , blotted and probed for the 
presence of tPA, uPA, PAl-1 and uPAR genes to give the results shown in figs. 
1.13 and 1.14. As is evident for this blot, the UCT-Mel 3 DNA digests contain a 
pattern of bands for the 4 genes that were similar, in size to the corresponding 
digest of HT1080 DNA One exception was the additional band in the UCT-Mel 3 
lane which hybridized to the tPA probe (fig. 1.13). 
Figure 1.13 
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Southern blot analysis of tPA, uPA and PAl-1 genes in UCT-Mel 3 and HT1080 
DNA 
10 µg of Hindlll and EcoRI digested UCT-Mel 3 Oane 1) and HT1080 (lane 2) DNA 
was electrophoresed on a O. 7% agarose gel and blotted onto Hybond N (as 
described). The blot was hybridized to 32P-labelled cDNA probes for tPA, uPA 
and PAl-1, washed and autoradiographed for 10 days. The mobilities of .X/Hindlll 
molecular weight markers are indicated. 
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Figure 1.14 
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Southern blot analysis of the uPAR gene in UCT-Mel 3 and HT1080 DNA 
10 µg of Hindlll and EcoRI digested UCT-Mel 3 Oane 1) and HT1080 DNA was 
electrophoresed on a 0.7% agarose gel and blotted onto Hybond N (as 
described). The blot was hybridized to a 32p-Jabelled cDNA probe for uPAR, 
washed and autoradiographed for 10 days. The mobilities of )./Hindlll molecular 
weight markers are indicated. 
47 
The band sizes obtained for uPA (single band > 2.7 kb) and PAl-1 (6.9, 4.8 and 
0.9 kb) corresponded to those expected from the published gene sequences. 
The sequence of the uPAR gene was unfortunately not available to me. For the 
tPA gene, the expected bands of 10 and 2 kb were obtained. However the 
remaining bands obtained (1.5, 1.2, 1.0 and 0.8 kb) did not correspond with the 
expected bands of 1.5, 1.4, and > 0.5 kb. [" >" is used to indicate 5' or 3' end 
fragments which may also contain bordering sequences]. 
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Discussion 
The results I report in this chapter warrant comment in a number of respects. 
Firstly, I have shown that cells from a highly metastatic cell line both failed to 
synthesize uPA and to transcribe detectable steady state levels of uPA mRNA. 
Since the gene for uPA was present in the cells, it is admittedly possible that they 
are induced to synthesize uPA when they took the form of a solid tumour in vivo 
and this capacity is lost when they are dispersed as an in vitro culture. I did not 
examine the freshly excised tumours of metastases, by immunohistochemistry or 
by preparing tumour lysates to see if this was the case so I am unable to discount 
this possibility entirely. If this did not occur one may conclude that invasion and 
metastasis is possible without the presence of human derived uPA. 
Since UCT-Mel 3 cells displayed uPA receptor one might argue that the uPA 
required for metastasis to occur could have been provided by the environmental 
host cells. This, however, is unlikely to occur in the nude mouse since human 
uPAR do not bind murine uPA (44, 57). Unlike U937 cells, UCT-Mel 3 cells 
appeared to express two classes of receptors - one with relatively high affinity, 
that was similar to the receptor found on other cell types and possibly a second, 
with low affinity, that was present in greater numbers. It is conceivable that 
murine uPA bound to the latter with an affinity sufficient to provide the proteolytic 
potential for spread. 
I found the binding experiments with 12s1-labelled ATF technically difficult to 
perform and interpret. It was evident that a large fraction of the labelled ATF, 
although physically intact, was functionally damaged and that the relative 
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concentration of non-functional ligand increased with storage. Background 
counts were therefore high and I was uncertain of the extent to which radio-
labelled, damaged ATF contributed to the non-specific binding values that I 
subtracted to derive data for the Scatchard plots. While I am confident that the 
data (figs. 1.1 O and 1.11) show specific and saturable binding of ATF to both 
U937 and UCT-Mel 3 cells, I am less confident of the values obtained from the 
scatchard plots. The ~ value which I obtained for the U937 cells (0.8 nM) differs 
from the 0.2 nM described for these cells in the literature (55, 57). My results also 
yielded a higher number of receptors/cell (50 x 103) than the 10-20 x 103 
previously quoted. 
I found it interesting that PAl-1 was not detectable in the parent cell line yet I was 
able to demonstrate transcription in the adrenal metastasis and translation in both 
the adrenal and lung metastases. Two obvious explanations for this finding come 
to mind: first, PAl-1 synthesizing cells may be a very small fraction of the total in 
the parental line and thus undetectable. If, by chance, the metastatic clone were 
derived from one of these cells this would have had the effect of concentrating the 
local presence to the level of detection. Secondly, the environment provided by 
the adrenal gland and lung may have induced UCT-Mel 3 cells to express PAl-1 
by mechanisms that were not operational in the primary tumour. 
The fact that PAl-1 was present in the metastases and not in the parental line 
none the less indicates that the presence of the inhibitor did not militate against 
spread. Studies on greater numbers of metastases are required to determine 
whether PAl-1 expression is a consistent feature. 
The results of the southern blots showed conclusively, that the lack of expression 
of uPA or PAl-1 (in the parental cells) was not due to gene deletion. Further than 
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the mechanisms that were involved in repression of uPA or PAl-1 in these cells 
remains to be elucidated. As I have indicated earlier, the lack of uPA transcription 
is a consistent feature of the melanoma phenotype and I think its study would be 
an interesting experimental investment. It has been shown that normal 
melanocytes secrete only tPA (102), although the cell culture method used 
involves addition of PMA, which may have altered the phenotype . It would, I 
believe, be reasonably straightforward to obtain answers to such questions as: 
• Is it possible to induce expression in melanoma cells with one of the agents 
known to induce the enzyme in other cells? 
• Would melanoma cells express uPA if transfected with the gene under the 
control of a different promoter? 
• Is protein synthesis required to maintain repression of uPA synthesis? 
• Are specific DNA binding proteins involved in the expression of uPA 
transcription? 
• Do melanoma cells in vivo express uPA while they do not do so in vitro? 
• Are regulatory sequences upstream from the uPA gene in melanoma cells 
consistently altered? 
Unfortunately I had neither the time nor the facilities to divert into this interesting 
aspect of melanoma cell biology. It is unusual to find human malignant cells that 
do not express uPA, melanoma cells are an important and consistent example. 
An interesting feature of the Southern blot for tPA was the presence of an 
additional band in the UCT-Mel 3 cell lane compared to the HT1080 lane. The 
possibility that this band may have arisen from partial digestion of the UCT-Mel 3 
DNA cannot be excluded, although the HT1080 DNA was digested under the 
same conditions. Since both cell lines produced functional tPA, this anomaly may 
be due to a mutation, possibly within an intron, which does not affect enzyme 
function significantly. 
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PART2 
Inhibition of tPA synthesis, clonal variation and presence tPA 
receptors in UCT-Mel 3 cells 
Introduction 
The results presented in part 1 showed, quite clearly, that a highly metastatic 
melanoma cell line neither released measurable uPA activity nor did it transcribe 
detectable uPA message (as detected by northern blot analysis). This finding led 
me to conclude that cell-derived urokinase activity is not an essential component 
of the metastatic phenotype. 
The question then arose as to whether or not tPA activity could substitute for uPA 
in the metastatic context. The data reported by Quax et al. (91) suggested that 
uPA activity was essential and that tPA alone was insufficient. This view accords 
in principle with the general view (123, 124), that uPA is primarily involved in tissue 
remodelling, while the role of tPA is largely fibrinolytic. 
To address this question, I felt that it would be useful, by genetic manipulation, to 
eliminate tPA synthesis in UCT-Mel 3 cells and to observe the effect upon the 
metastatic potential of tumours derived from the cells. Three approaches were 
available to me to achieve this: 
• the stable transfection of antisense tPA gene fragments into the cells; 
• the transfection of a specific anti-tPA mRNA ribozyme sequence into the 
cells; 
• the transfection, into the cells, of a functional PAl-1 gene that would code 
for the synthesis of sufficient inhibitor to neutralize all tPA activity. 
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Antisense 
The use of antisense constructs to inactivate specific message has been widely 
and effectively applied in vitro (see 125, 126 for review) . In experiments of this 
sort, single-stranded DNA oligonucleotides are added to the culture medium at 
concentrations high enough to ensure their intact passage into the cells where 
they bind message and effectively block translation. Such a strategy was 
obviously not appropriate for the long term in vivo studies I wished to undertake. 
I therefore chose an approach in which I would transfect the cells with genetic 
constructs in which segments of DNA under a strong promoter would be 
constitutively transcribed to yield neutralizing antisense mRNA. Transfected 
clones would be selected for their lack of tPA secretion and these would be used 
to assay metastatic potential in the nude mouse. 
For this purpose I chose a plasmid vector that I obtained from Dr. Pat Clissold 
(MIP unit, MRC, Cambridge). This contained a suitable cloning site into which the 
anti sense gene could be cloned downstream of the potent CMV promoter, as well 
as a gene conferring Hygromydn resistance in mammalian cells. The plasmid 
had been transfected into human cells by Dr. Clissold to obtain stable expression 
(personal communication). The plasmid was supplied with the CAT gene in the 
cloning site; this could thus be used to ensure that the promoter was active in 
UCT-Mel 3. 
Ribozymes 
After the discovery (127) that RNA molecules could, when endowed with specific 
sequences and conformations, exert hydrolytic activity, it was to be expected that 
sequences encoding specific "designer" ribozymes would be transfected into 
eukaryotic cells with a view to destroying cognate message. 
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A number of reports have attested to the useful validity of this approach (128-
130). Generally speaking, for an RNA molecule to have RNAse activity it should 
contain a defined sequence which forms a "hammerhead loop" that is flanked by 
two short sequences which are complementary to sequences flanking a target 
site which must contain a GTC triplet (fig. 2.48). The ribozyme binds to the 
complementary sequences of the target mRNA and catalyses cleavage between 
the T and C of the target site (131 ). 
All reports up to the time at which I performed the experiments dealt specifically 
with transient transfection of ribozyme oligonucleotides. In none of these had the 
authors attempted to achieve long term constitutive expression of a transfected 
DNA fragment that would encode a functional ribozyme. I saw no a priori reason 
why this should not be possible and I accordingly undertook a series of 
experiments that were designed to eliminate tPA synthesis by this method. One 
of the advantages offered by this approach was the fact that it was possible by in 
vitro transcription from a T7 or SP6 promoter to obtain ribozyme and confirm its 
enzyme activity using radio labelled target message. 
PAl-1 
As noted in chapter 1, parental UCT-Mel 3 cells do not synthesize detectable 
amounts of PAl-1 - a potent inhibitor of tPA activity. A way, therefore, of achieving 
inhibition of tPA activity would be to obtain stable transfectants of UCT-Mel 3 cells 
expressing PAl-1 in amounts sufficient to neutralize all cellular and extracellular 
tPA activity. This was a project undertaken by Mr. G.S. Hanekom, one of my 
colleagues in the laboratory. He successfully transfected cells with human PAl-1 
under the control of the CMV promoter and was able, in short term experiments 
to achieve complete abrogation of all detectable tPA activity. 
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Although seemingly straightforward, the antisense and ribozyme experiments did 
not give the results that I had hoped for. They did, however, raise a number of 
other issues that should provide interesting ground for further work. 
As I shall report in this chapter the CMV promoter functioned effectively in UCT-
Mel 3 cells when the CAT construct was transfected. I then went on to transfect 
the antisense construct in the confident hope that, by selecting with Hygromycin, I 
would be able to isolate clones with absent or diminished tPA activity. It 
transpired however, that effective Hygromycin selection was thwarted by the 
development of drug resistant clones whose ability to survive the antibiotic was 
unrelated to the presence of the resistance gene and was probably due to 
acquisition of a Hygromycin export mechanism similar to that which has been 
found in other chemoresistant malignant cells (132). The Hygromycin resistant 
clones that I subsequently selected for diminished tPA activity no longer 
contained the antisense construct. The low tPA activity appeared to be due to 
clonal variation within a highly heterogeneous and phenotypically unstable cell 
line. 
In a final attempt to derive cells that could be used to study the relationship 
between tPA release and invasiveness, I isolated 20 clones from an untransfected 
culture. These I characterized with respect to !PA release, growth rate and 
morphology. Unfortunately, I have not been able to assay their capacity for 
invasion or spread in the nude mouse. 
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Methods 
"Sense" and "antisense" plasmids 
Two plasmids were used to prepare sense and antisense constructs for 
transfection; p17-CAT (a shuttle vector that was generously provided by Dr. Pat 
Clissold, MIP Unit, Cambridge) contained a ,8-lactamase gene (for selection in E. 
Coli); a gene conferring Hygromycin resistance (for selection in mammalian cells); 
the cytomegalovirus (CMV) promoter (for expression of cloned genes in 
mammalian cells); and the chloramphenicol acetyl transferase (CAT) gene under 
the control of the CMV promoter (fig. 2.1 ). 
'iO C'.' 
Figure 2.1 
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P17-CAT contains the chloramphenlcol acetyl transferase gene (CAT) under the 
control of the cytomegalovirus (CMV) promoter. The gene conferring Hygromycin 
resistance in mammalian cells Is under the control of the SV40 promoter. 
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pW349F (119) was kindly provided by Dr. S.J. Friezner-Degen. This plasmid 
contained a 2519 bp insert of human tPA cDNA cloned into the Pstl site of 
pBR322. Both plasmids were maintained in E. Coli DH5. 
A 1976 Bglll fragment containing the mature coding sequence for tPA was 
excised from PW349F and ligated into p17, from which the CAT gene had been 
removed with BamHI (fig. 2.2). Bacteria (E. Coli, DH5) were transformed with the 
ligation product. Colonies picked from ampicillin containing plates and minipreps 
were prepared to establish the presence of the correct plasmid. 
The orientation of the insert with respect to the CMV promoter was determined by 
digestion with Bglll and Smal. Single colonies containing sense (p17-tPAs) and 
antisense (p17-tPAas) were grown to prepare DNA for transfection. The standard 
techniques used to prepare the plasmids are described in the appendix (A.22). 
Transfection and selection for Hygromycin resistance 
The UCT-Mel 3 cell line was titrated with various concentrations of Hygromycin B 
(Boehringer Mannheim) to determine the correct concentration that would be 
required to select transfected clones. Cells were seeded into 35 mm dishes at a 
density of 2 x 105/dish in RP10 containing Hygromycin Bat concentrations of 150, 
100, 50, 20, 10, 5 and 2 µg/ml. On days 0, 2, 4 and 7, cells were detached and 
trypan blue viability counts performed. Viable cell counts, obtained in the 
presence of varying Hygromycin concentrations, were plotted as a function of 
time (fig. 2.3). The appropriate concentration for selection was taken as the 
lowest concentration which inhibited growth completely, namely 50 µg/ml. 
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Construction of p17-tPAa and p17-tPAaa plasmids 
c17A.NTI -:: EN ~E 
747 ,::. 
pW349F was digested with Bglll, releasing a 2000 bp fragment of the tPA cDNA, this Bglll/tPA 
fragment was then ligated into the BamHI site of p17. The orientation of the tPA insert of 
recombinants was ascertained by digestion with Smal and Bglll. 
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Hygromycin titration 
2 4 6 8 
TIME (days) 
10 12 
a O µg/ml 
"" 5 µg/ml 
T 10 µg/ml 
o 20 µg/ml 
• 50 µg/ml 
Various concentrations of Hygromycin B were added to UCT-Mel 3 cells 
throughout a growth curve (starting at a cell density of 2X105 cells/35 mm dish). 
The number of viable cells was counted at each time point. 
Plasmids (p 17-CAT, p 17-tP As and p 17-tP Aas) were prepared for transfection by 
purification on cesium chloride gradients, linearizing with Bglll and precipitating 
with ethanol. UCT-Mel 3 cells (47') were washed in HEPES buffered saline (HBS) 
pH 7.04 and then resuspended at 5 x 106/ml in HBS containing plasmid at 20 
µg/ml. Cells were incubated on ice for 15 min before transferring 0.4 ml of the 
suspension to a sterile electroporation chamber, where they were exposed to a 
high voltage pulse (1100 V) that was empirically determined as that which killed 
75% of cells (133). Cells were then incubated on ice for 15 min, transferred to a 
100 mm dish containing 1 O ml RP1 O and grown for 3 days without selection. Cells 
were then detached from the dishes and replated at various dilutions in RP10 
containing Hygromycin at 50 µg/ml. Cells were fed twice weekly with fresh 
Hygromycin containing medium. 
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It was not possible to pick single cell clones from the selected dishes of adherent 
cells because of the significant number of floating cells present in the cultures. 
For this reason I cloned the cells in soft agar (A.16). Hygromycin was removed 
from the cultures before cloning and then replaced when clones were transferred 
into 35 mm dishes. 
CAT assay 
Cell lysates were prepared from both p17-CAT transfected cells (after three weeks 
of Hygromycin selection) and parental UCT-Mel 3 cells and assayed for CAT 
activity (A.25), by measuring the transfer of 14C from 14C-chloramphenicol to 
acetyl Co-A. 
PA release by transfected UCT-Mel3 cells 
Cells were plated in duplicate in 24 well plates at densities of 5x104 and 1 os cells 
per well. The following day, serum free medium was added (500 µI/well) and then 
collected after 24 hr. Samples were assayed using a chromogenic assay (A.30), 
with a tPA standard curve. Values were expressed as units/106 cells/24 hr) and 
plotted against cell number (log scales). 
PCR 
Three primers were designed with the aid of the GCG Primer program (table 2.1 ). 
One primer, targeted to the CMV promoter region was used as forward primer for 
p17-CAT and p17-tPAs with the reverse primer targeted to the poly A region. This 
primer pair thus amplified the entire cDNA sequence. In order to amplify a part of 
the antisense construct, a primer specific for a site within the 5' end of the tPA 
gene was used as forward primer, while the poly A primer was used as reverse 
primer (see fig. 2.28). Standard concentrations of dNTP's and primers (A.26) 
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were used for all PCR reactions and MgCb concentration was optimized for each 
primer pair. In all cases an initial denaturation step (95°C for 180 sec) was 
performed. Cycling conditions were determined empirically for the two different 
primer pairs. 
Cycling conditions for CMV /poly A primer pair: 
9s0c -1so s l 
61°C -30 s x1 
72°c -30 s 
9s0c -3o s l 
61°C -30 s x9 
72°c -3o s 
95°C-30 s 
58°C -30 s 
72°c -3o s 
Cycling conditions for tPA/poly A primer pair: 
gs0c -180 s l 
61°C -30 s x1 
72°c -so s 
9s0c -3o s J 
51°c -3o s x9 
7'2?C -60 s 
Table 2.1. PCR primers 
ID SEQUENCE 
(5 1 -3 1 ) 
CMV AACAACTCCGCCCCATTGAC 
POLY A CACCTCCCCCTGAACCTGAA 
tPA TGAAACACCTTGGCTCGCTG 
parameters for GCG • primer": 
length= 17-28 bases 
(G+C)%=55-60 
Tm=60-65% 
3'-complementarity < 3 
self-complementarity <4 
9s0c -3o s 
58°C -30 s 
7'2?C-60 s 
~C) 
64.4 
64.6 
64.7 
J ~5 
1~5 
GC% SELF- 3'- -MER 
COMP COMP 
55 3 1 20 
60 2 1 20 
55 2 2 20 
60 
-oOCO 
p17SENSE 
7476 
<tiJCO 
-
!.1CO 
74?11 
I 
Figure 2.28 Diagram showing the positions of primers used for PCR amplification of p17-CAT, 
p17-tPAs and p17-tPAas 
) =CMV, ) =POLYA, ) =tPA 
Ribozyme construction 
The tPA sequence was searched for GTC triplets and the sequences flanking 
each site were added to the ribozyme loop sequence and their proposed 
secondary structure analyzed using the Genetics Computer Group (GCG) 
"Squiggles" program. All sequences which did not assume the correct folding 
required for ribozyme activity were discounted. Position 577 within the tPA gene 
was finally chosen as a suitable ribozyme target site. The ribozyme sequence 
(fig. 2.4A) was synthesized (Prof. D. Bates, Dept. Biochemistry, UCT) as two 
complementary oligonucleotides, incorporating restriction enzyme cohesive ends 
(5 '-Hindlll, 3'-BamHI) for cloning purposes. The oligonucleotides were hybridized 
by mixing, heating to 900C and cooling slowly. The ribozyme sequence was then 
cloned into the BamHI and Hindlll sites of a transcription vector (pSP64, 
Promega), from which transcripts could be produced for testing ribozyme activity 
in vitro. The sites were also suitable for cloning into an expression vector for 
transfection purposes. 
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Figure 2.4 
A. Sequence of the anti-tPA ribozyme oligonucleotldes 
Sequence of the ribozyme oligonucleotlde sequence which was cloned into the Hindlll and BamHI 
sites of pSP64. The 5' end was ligated adjacent to the SP6 promoter of pSP64, from which the 
ribozyme RNA was transcribed. The recombinant pSP64-R1B was linearized at the BamHI site 
prior to transcription. 
B. Secondary structure of the anti-tPA ribozyme 
Predicted hammerhead structure of the rlbozyme RNA (blue stand) annealed to its target tPA 
mRNA sequence (green strand). The GUC cleavage site at position sn within the tPA mRNA is 
shown in red. The plot was generated by the GCG "Squiggles" program using the output from 
Fold. 
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Cloning of tPA gene into pGEM 1 
The 1976 bp Bglll tPA fragment prepared from pW349F was ligated into the 
BamHI site of pGEM 1 and transformed into competent E.Coli. Minipreps were 
prepared to establish the presence and orientation of the inserts. 
Transcription 
The pGEM1-tPA and the pSP64-RIB templates were linearized by digestion with 
Hindlll and BamHI respectively. The digests were then extracted with 
phenol/chloroform and ethanol precipitated. 3H-UTP labelled ribozyme and tPA 
transcripts were prepared (A.31 ), with SP6 and T7 RNA polymerases respectively, 
using the Promega Gemini kit. 
For the ribozyme reaction, tPA (0.1 µM) and ribozyme (3 µM) transcripts were 
combined in 50 mM Tris.Cl (pH 8.0), 20 mM MgCl2, RNAsin (2000 U/ml), and 
incubated at 50°C for 30 min. Samples were then electrophoresed on a 4% 
denaturing polyacrylamide/urea gel which was treated as described (A.30) and 
exposed to x-ray film. 
Isolation and analysis of UCT-Mel 3 clones 
Single cell clones of the UCT-Mel 3 cell line were obtained by cloning in soft agar 
(A. 16). Growth curves were performed for each clone (A. 17). 
Plasminogen activator release 
Conditioned medium (A.18) was collected from UCT-Mel 3 clones at densities of 
105, 2 x 105 and 106 cells/60 mm dish (plated in triplicate) and assayed in the 12s1-
fibrin assay (A.7), using a uPA standard curve. Samples were diluted ten-fold 
before assay. 
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PAl-1 ELISA 
UCT-Mel 3 conditioned media (undiluted) were tested for PAl-1 antigen using the 
American Diagnostica PAl-1 ELISA kit (#822/5). 
tPA receptor 
UCT-Mel 3 cells were acid treated (A.31) to remove cell-surface associated tPA, 
washed and then 106 cells were incubated (2 hr, 4°C) with increasing 
concentrations of tPA in 200 µI of binding medium (Hepes buffered RPMI 
containing 0.5% BSA). The cells were washed 4 times in binding medium to 
remove unbound tPA and then acid treated. Neutralized eluates were collected 
and assayed for tPA activity in the 12s1-fibrin plate assay. 
Results 
Sense and antisense plasmids 
The 1976 bp Bglll fragment of the tPA gene was successfully cloned into the p17 
vector in both sense and antisense orientations. Recombinant clones were 
checked by simultaneous digestion with Bglll and Smal, which yielded fragment 
sizes of 6175 and 1296 for sense t-PA (p17-tPAs), 5099 and 2372 for antisense t-
PA (p17-tPAas) and a single band of 6270 for no insert (fig. 2.5). Plasmids p17-
tPAs and p17-tPAas were then amplified and purified by CsCI purification (A.22) in 
preparation for transfections. 
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1 23 45 6 7 
Figure 2.5 
Orientation of p17-tPA insert 
2.3 
2.0 
Putative recombinant plasmid minipreps were digested with Smal and Bglll in 
order to determine the orientation of the tPA insert. Digestion yielded bands of 
6175 and 1296 bp for sense clones Oanes 4-8) and bands of 5099 and 2372 bp for 
antisense clones (lanes 1,2). A/Hindlll size markers were run in lane 9. Lane 3 
represents p17 lacking an insert. 
Transfection by electroporation 
CAT expression was measured in lysates prepared from UCT-Mel 3 cells 
transfected with p17-CAT, which had been under Hygromycin selection (50 
µg/ml) for 3 weeks. Lysates prepared from untransfected cells were used as a 
negative control. Appreciable levels of CAT were measured in CAT transfected 
cells (0.06 units) and untransfected cells were negative (fig. 2.6). Once the 
expression of the CAT gene under the CMV promoter had been confirmed, I went 
on to transfect p17-tPAs and p17-tPAas, with subsequent Hygromycin selection. 
Hygromycin resistant cells appeared as islands of growth after approximately 
three weeks, however the presence of many floating cells within the UCT-Mel 3 
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cultures resulted in the formation of rather untidy and indistinct clones. Since it 
was impossible to pick single clones using cloning rings, the selected cells were 
cloned in soft agar. Cells which had been electroporated in the absence of DNA 
were selected with Hygromycin in parallel and these were also found to produce 
resistant clones. 
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Figure 2.6 
CAT assay standard curve 
Standard curve obtained from dilutions of a standard CAT preparation. The bar 
indicates the value of 0.06 extrapolated from the cpm obtained from assaying 50 
µI of a 150 µI cell lysate prepared from UCT-Mel 3 cells transfected with p17-CAT 
and subsequent Hygromycin selection. Thus CAT produced from a confluent 100 
mm dish corresponds to 0.18 units. 
Cloning of transfectants 
Agar cultures are not fed freshly, thus Hygromycin which should be replenished 
every 3-5 days was omitted. Clones were picked after 14 days and transferred to 
microtiter plates. Clones were successfully grown from the p17-tP~ (5 clones) 
and p17-tPAas (15 clones) transfected cultures respectively and frozen down. 
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tPA release by electroporated clones 
Release of tPA by cells grown from Hygromycin-resistant clones that had been 
electroporated with p17-tPAas was measured in the hope that I would find stable 
transfectants that no longer synthesized tPA (table 2.2). 
Table 2.2. Plasminogen activator release by UCT-Mel 3 cells transfected 
with p17-tPAa, 
CLONE PA ( l) REGRESSION PARAMETERs( 2 ) 
I 
M C r 
PARENT 63.979 -0.638 ± 0.031 4.804 ± 0.152 0.984 
1 35.550 -0.839 ± 0.099 5.498 ± 0.474 0.993 
4 30.660 -0.472 ± 0.114 3.705 ± 0.544 0.972 
5 63.681 -0.408 ± 0.086 3.721 ± 0.402 0.959 
7 57.483 -0.540 + 0.090 4.297 ± 0.432 0.973 
I 8 57.429 -0.429 ± 0.160 3.775 ± 8.755 0.884 
9 59.952 -0.707 ± 0.145 5.100 ± 0.679 0.980 
11 16.330 -0.495 ± 0.004 3.539 ± 0.021 0.999 
I 
15 42.846 -0.106 ± 0.110 2.131 ± 0.519 0.563 
17 
I 
24.222 -0.014 ± 0.090 1. 451 ± 0.421 0.105 
18 24.560 -0.333 ± 0.114 2.955 + 0.541 0.947 
19 49.345 -0.446 ± 0.126 3.789 ± 0.580 0.929 
20 
I 55.213 -0.339 ± 0.095 3.335 ± 0.450 0.929 
(1) PA release calculated from regression for a cell density of 5 x 104 cells/60 mm dish 
(2l Regression parameters given for the equation: 
(log y) = m(log x) + c 
y=PA release/Hf cells/24 hr 
x=cells/60 mm dish 
r = correlation coefficient 
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I 
Due to the inverse relationship between PA release and cell density, (see fig. 
2.12), the values obtained were converted to units/106 cells/24 hr and plotted 
against cell density. Log scales were used in order to obtain a linear relationship. 
The results (table 2.2) showed very variable levels for tPA release ranging from 16 
to 63 units/106 cells/24 hr (calculated for a cell density of 5x1Q4 cells/16 mm 
well). I found no clones in which release of the enzyme had been totally 
abolished, although in some clones the PA activity_was lower than in the parental 
UCT-Mel 3. 
PCR analysis of electroporated clones 
I used the primers described in the methods section to analyze the transfected 
Hygromycin resistant clones by PCR with the results shown in figs. 2. 7 and 2.8. 
A B 
Figure 2.7 
PCR detection of p17-tPAaa in cell lysates of transfected UCT-Mel 3 clones 
PCR products were electrophoresed on a 1.5% agarose gel 
A lane 1, pGEM1 /Hinfl size markers; lane 2, no DNA control; lane 3, p17-
tPAas plasmid as positive control; lane 4-7, antisense clones 
B lane 2, pGEM/Hinfl; lane 3, p17-tPAas; lanes 1, 4-8, antisense clones 
68 
Of the clones electroporated with p 17-tP As, both those tested contained the 
plasmid (fig. 2.8). In none of those electroporated with p17-tPAas was I able to 
demonstrate transfected DNA (fig. 2. 7). PCR amplification of the p 17-CAT 
transfected cells produced the correct band (fig. 2.8), as expected from the CAT 
assay result. 
A B 
Figure 2.8 
PCR detection of p17-tPAs and p17-CAT in cell lysates of transfected UCT-
Mel 3 clones 
PCR amplification products were electrophoresed on a 1.5% agarose gel 
A lane 1, )./Hindlll markers; lane 2, pGEM/Hinfl markers; lane 3, no DNA 
control; lane 4, p17-tPAs plasmid; lane 5, untransfected UCT-Mel 3; lane 6, 
p17-tPAs transfected clone 2; lane 7, p17-tPAs transfected clone 29. 
B. lane 1, pGEM/Hinfl markers; lane 2, no DNA control; lane 3, p17-CAT 
plasmid; lane 4, untransfected UCT-Mel 3; lane 5, p17-CAT transfected 
UCT-Mel 3 DNA. 
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Ribozyme construction 
The ribozyme targeted to position sn of tPA mRNA was successfully cloned into 
the pSP64 vector. This was confirmed by digesting transformants with Hindlll and 
BamHI. Digestion of recombinants released the 44 bp ribozyme fragment, 
compared to 27 bp for the vector alone (representing a fragment of the multiple 
cloning site). These bands were too small to be visualized on an agarose gel and 
hence were separated on a 20% nondenaturing polyacrylamide gel (fig. 2.9). 
Figure 2.9 
Cloning of the antl-tPA rlbozyme Into pSP64 was confirmed by digestion with 
Hindlll and BamHI. The digest was electrophoresed on a 20% non-denaturing gel. 
lane 1, pSP64-R1B digested with Hindlll and BamHI (44 bp). lane 2, pSP64 
digested with Hindlll and BamHI (27 bp). lane 3, pGEM/Hlnfl marker 
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tPA template preparation 
Digestion of the transformants with Smal produced bands of 3307 bp and 1532 
bp for sense recombinant plasmids (fig. 2.10) compared to a single 2998 bp band 
for vector alone. The plasmid DNA from a pGEM 1-tPAs containing colony was 
amplified and purified over a CsCI gradient and used as a template for 
transcription from the T7 promoter. 
--- ------
kb 1 2 3 4 5 6 
Figure 2.10 
Orientation of pGEM1-tPA insert 
The tPA/Bglll fragment (2000 bp) was cloned into the Bglll site of pGEM1. 
Orientation of the fragment was determined in putative recombinant minipreps by 
digestion with Smal. 
lane 1, A/Hindlll markers; lanes 2 and 3, sense oriented recombinants (sizes 3307 
and 1693 bp); lanes 4-6, non-recombinants (2998 bp). 
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Testing of ribozyme on synthetic tPA RNA substrate 
The 3H-labelled ribozyme and tPA transcripts were found to be intact and of the 
correct size (44 bp and 1100 bp respectively) after denaturing PAGE and 
subsequent auto radiography (fig. 2.11). The tPA transcript showed some 
evidence of either premature termination or degradation in the form of lower MW 
bands. After incubation of the tPA substrate with the ribozyme followed by 
electrophoresis and autoradiography, no digestion of the tPA transcript was 
observed. 
4242 
Figure 2.11A 
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Transcription of ribozyme and tPA template 
Diagrammatic representation of pSP64-RIB and pGEM1-tPA: 
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pSP64-RIB was digested with BamHI and Nhel and the fragment containing the SP6 promoter and 
ribozyme insert was gel purified. The ribozyrne was then transcribed using SP6 RNA polymerase. 
pGEM1-tPA was digested with Pvull and the fragment containing the T7 promoter and the 5' end of 
the tPA sequence was gel purified. The tPA RNA was then transcribed using T7 RNA polymerase. 
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Figure 2.11 B 
Transcription of rlbozyme and tPA template and testing for ribozyme 
catalysis of tPA RNA 
Ribozyme and tPA mRNA were transcribed with the Incorporation of 3H-UTP, 
electrophoresed on a 4% denaturing polyacrylamlde gel which was then fDCed, 
fluorographed, dried and autoradlographed. 
lane 1, ribozyme transcript (44 bp) 
lane 2, tPA transcript (1195 bp) 
lane 3, tPA transcript after treatment with rlbozyme 
The mobRlties of standard transcripts produced from templates provided In the kit 
are Indicated. 
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Clonal analysis of UCT-Mel 3 
The variation in levels of tPA release seen in the Hygromycin-resistant clones 
indicated that UCT-Mel 3 cells are phenotypically unstable and heterogeneous. 
To document the extent of this variability and to correlate it, if possible, with 
invasiveness and metastatic potential, I prepared 20 clones from a single 40-
passage culture and characterized these in terms of their morphology, tPA 
release and doubling time. The results are presented in fig. 2.12, 2.13 and table 
2.3. The non-linear relationship between PA release and cell density required that 
results were plotted as log (units /1rJS cells/24 hr) against log cell density. This 
produced a linear graph from which results could be calculated for a particular cell 
density. 
As is evident from the data, clones that varied considerably in this respect could 
be derived from the parent culture. Morphologically, cells within any clone were 
fairly homogeneous at early passage. As shown in fig. 2.12, most clones grew as 
adherent monolayers, whereas others grew as a semi-adherent layer with many 
rounded but nevertheless viable cells (eg. 1 D6). No pigmented cells were seen. 
Most grew as flattened polygonal or triangular cells, similar to the parental cells 
(eg. 1C5, 2A4). The more spindle shaped morphology of clone 184 was 
particularly noticeable. Other clones were distinctly dendritic with long processes 
(eg. 284, 1 D3). Clones 3D3 and 183 were distinguished by the tendency for cells 
to pile up into large amorphous clumps, even when subconfluent. Another 
feature was size variation amongst the clones, with the existence of giant cells in 
some clones (eg. 1A1, 1A6, 183). Some of these large cells took on a very 
spread out, flattened appearance (1A6, marked by arrow). 
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Figure 2.12A 
Morphology of UCT-Mel 3 clones 
UCT-Mel 3 clones were plated at a density of 10s cells/60 mm dish and photographed at 100x 
magnification on a phase contrast microscope. 
Figure 2.120 
Morphology of UCT-Mel 3 clones 
UCT-Mel 3 clones were plated at a density of 106 cells/60 mm dish and photographed at 100x 
magnification on a phase contrast microscope. 
Table 2.3. Plasmlnogen activator production by UCT-Mel 3 clones. 
CLONE DT(hr) PA (1) REGRESSION PARAMETERS 
M C 
lAl 100 14.351 -0.691 ± 0.043 4.612 ± 0.226 
1A3 48 7.197 -0.356 ± 0.040 2.637 ± 0.216 
1A6 61 7.609 -0.463 ± 0.045 3.195 ± 0.249 
1B3 66 14.991 -0.701 ± 0.044 4.679 ± 0.244 
1B4 38 7.395 -0.702 ± 0.073 4.380 ± 0.408 
1C2 71 20.151 -0.770 ± 0.069 5.155 ± 0.372 
1C5 58 7.161 -0.651 ± 0.117 4.111 ± 0.639 
103 50 7.290 -0.650 ± 0.103 4.115 ± 0.560 
106 83 10.224 -0.679 ± 0.061 4.404 ± 0.326 
2A4 69 7.643 -0.391 ± 0.047 2.840 ± 0.255 
2A5 52 14.348 -0.721 ± 0.046 4.762 ± 0.250 
2Bl 35 16.935 -0.684 ± 0.054 4.674 ± 0.294 
2B4 76 16.009 -0.753 ± 0.043 4.970 ± 0.233 
2C6 57 12.246 -0.623 ± 0.065 4.202 ± 0.351 
202 65 10.879 -1.006 ± 0.068 6.068 ± 0.375 
3A4 54 7.440 -0.702 ± 0.073 4.380 ± 0.478 
3B4 58 12.399 -0.642 ± 0.022 4.304 ± 0.117 
3B5 46 10.818 -0.508 ± 0.058 3.576 ± 0.318 
303 61 16.429 -0.561 ± 0.043 4.019 ± 0.218 
MEL 3 55 3.82 -0.274 ± 0.048 1.952 ± 0.271 
(1) PA release calculated from regression for a cell density of 1<>5 cells/60 mm dish <2> Regression parameters given for the equation: Oog y) = mOog x) + c 
y=PA release/1a6 cells/24 hr 
x=cells/60 mm dish 
r = correlation coefficient 
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(2) 
r 
0.987 
0.959 
0.968 
0.986 
0.964 
0.973 
0.928 
0.923 
0.973 
0.953 
0.986 
0.979 
0.989 
0.965 
0.984 
0.964 
0.996 
0.958 
0.980 
0.908 
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PA release by UCT-Mel 3 clones was measured In the fibrin plate assay. Results were converted to 
units/10S cells/24 hr and plotted against cell density on a log scale to obtain a linear relationship. 
These graphs are representative examples. 
Doubling times were distributed over the range 38 to 100 hr (table 2.3). The rate 
of tPA release by each clone was consistently inversely related to cell density. 
Plots of log rate of enzyme release (measured as units/106 cells/24 hr) as a 
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function of log cell density gave linear plots with the parameters and correlation 
coefficients presented in table 2.3 . Typical plots showing this inverse relationship 
are shown in fig. 2.13. To compare PA release by different clones it was thus 
necessary to correct for cell density. This was done by calculating the 
interpolated value for the rate of tPA release corresponding to a cell density of 105 
cells/60 mm dish. Values varied considerably from 3.82 to 20 units. No 
significant relationship between PA release and doubling time could be discerned. 
PAl-1 ELISA 
PAl-1 antigen was undetectable in all UCT-Mel 3 clone conditioned media as well 
as the parental line when tested in the PAl-1 ELISA (detection limit <0.5 ng/ml). 
Human serum (diluted 40-fold), used as a positive control, had a PAl-1 
concentration of 2 ng/ml. 
Cell surface receptor for tPA 
If, by analogy with the proposed mechanisms for uPA-mediated spread, tPA were 
to be involved in the migratory process, one would expect cells to express surface 
receptors for tP A. 
My attempts to measure such receptors or to show saturable association of cells 
with enzyme using radio-labelled tPA were not at all successful. I had, perforce to 
use whole intact tPA for labelling and binding studies, since I did not have a well 
defined "receptor ligand domain", similar to the ATF of uPA to work with. Labelled 
tPA gave erratic results in binding studies; background counts were high and I 
was unable to maintain reasonably physiological conditions in the effort to reduce 
non-specific binding. 
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I thus resorted to a technique in which UCT-Mel 3 cells were treated with acid to 
remove such residual enzyme as may be present. The cells were then incubated 
with different concentrations of tPA and washed. Bound tPA was eluted with 
glycine, pH 3.0, measured and plotted as a function of the amount of tPA added. 
A typical plot is shown in fig. 2.14. From the data obtained, an approximate Kci of 
4 nM (corresponding to 50% of maximum binding) and total cellular capacity for 
tPA binding of 50 000 molecules/ cell could be estimated. 
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Figure 2.14 
Binding of tPA to the surface of UCT-Mel 3 cells 
Acid treated UCT-Mel 3 cells were Incubated with various concentrations of tPA (2 hr at 4°C). Cells were washed, eluted with acid to remove surface associated 
molecules, and the tPA In eluates measured with the fibrin plate assay. 50% of 
maximal binding occurred at approximately 4 nM. 
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Discussion 
The experimental strategy that I chose to define a role for tPA in the metastatic 
process proved to be unsatisfactory in two respects. First, I was unable to 
develop a line of cells in which the synthesis of tPA was abolished and, second, 
had I been able to do so, the failure of such cells to develop into metastasizing 
tumours could have reflected an irrelevant clonal difference that was unrelated to 
eliminated protease activity. Had, of course, such cells been as tumourigenic and 
metastatic as the parental line, I could have concluded that tumour-derived tPA 
was not involved, but such a result would have been interesting in a negative 
sense. It would have contributed little to an understanding of the biochemistry of 
invasion or spread. 
I did not expect the genetic manipulation to be unsuccessful nor did it occur to me 
that phenotypic instability and clonal variation within an established cell line would 
be so pronounced. Nevertheless, the unforeseen problems provide interesting 
grounds for comment. 
I have no explanation to offer for the failure of the ribozyme to cut the tPA 
transcript, save for the possibility that the site which I chose may have been 
obscured or unavailable for binding to the ribozyme due to secondary structure. 
Heidenreich et al. (134) have shown that longer substrates were 1000x less 
efficiently cleaved by a ribozyme than oligonucleotides and also that at a 
particular site, cleavage of the longer substrate was much less efficient that at 
other sites. It is possible therefore, that I would have had more success if I had 
synthesized a number of ribozymes targeted to different GTC sites. In view of the 
fact that I could not demonstrate hydrolytic activity, I felt it would be pointless to 
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proceed to the next step of cloning the ribozyme into an expression vector and 
transfecting the construct into melanoma cells. 
The experiments in which I transfected UCT-Mel 3 cells with the anti-sense tPA 
construct were, perhaps, more interesting. Expression of the CAT reporter gene 
in transfected cells showed quite clearly that the CMV promoter in p17 functioned 
efficiently and stably. Furthermore, clones that had been electroporated with p17-
tPAs could be shown to contain the plasmid. Why then, was p17-tPAas not 
retained? In these particular cells, selection with Hygromycin was inefficient in the 
sense that they proved to be capable of acquiring Hygromycin resistance by a 
mechanism that was unrelated to the presence of the antibiotic gene. This well 
described property of malignant cells (132) had allowed non-transfected clones to 
develop. Nevertheless in view of the efficacy of the promoter and the 
demonstrable presence of p17-tPAs-transfected clones, I am surprised that the 
clones carrying Hygromycin resistance in p17-tPAu did not have at least some 
advantage that would have enabled me to isolate them. This raises the interesting 
(and entirely speculative!) possibility that the translation of tPA message is 
essential for the survival of melanoma cells. If this were so, clones effectively 
transfected with p17-tPAas would have failed to synthesize tPA and they would 
have been eliminated from the proliferating population, leaving only Hygromycin-
resistant mutants to survive. 
Experimental confirmation of this notion might come from experiments in which 
antisense tPA oligonucleotides were added to melanoma cell cultures and the 
effects on proliferation noted. If, indeed, tPA synthesis is required for melanoma 
cell proliferation one should observe inhibition. It is possible that tPA is directly 
required for cell growth. Perhaps a more likely explanation though, is that plasmin 
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is required for the release/activation of growth factors such as bFGF (rev. 77), 
which are responsible for modulating cell proliferation. 
As these melanoma cells approach confluence in culture so the rate at which they 
release tPA diminishes (fig. 2.12). This observation can be used, to some extent, 
to support the suggestion that a direct relationship exists between rate of 
proliferation and rate of tPA synthesis. This , however, was only true for any given 
clone. No correlation was observed when doubling times were plotted as a 
function of rate of tPA release. 
Had I been successful in obtaining antisense transfectants producing reduced 
tPA, the problem of the clonal variation within the cell fine would have made the 
results difficult to interpret, particularly with regard to the metastatic assay in the 
nude mouse. For example, I discovered that upon injection into nude mice, clone 
11 did not even form a primary tumour (results not shown), thus any 
characteristic of a clone could not be attributed necessarily to the transfected 
phenotype. A solution to this problem would be to transfect the antisense gene 
under the control of an inducible promoter. Thus the uninduced clone could first 
be compared to the parental line and then only induced to produce antisense. 
This strategy would also allow antisense transfected, tPA dependent cells (as 
suggested above) to be cloned. 
The evolution of metastatic cells in a primary tumour may be regarded as 
equivalent to in vivo cloning in the sense that it is probably only a small fraction of 
the population that has, or develops, the capacity to spread. This view casts 
doubt on the relevance of experimental approaches that study the whole 
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population. One should, perhaps, examine several metastases for common 
features. 
It is unfortunate that I was not able to demonstrate a specific tPA receptor on the 
UCT-Mel 3 cells, as this would have provided a mechanism of invasion in the 
absence of uPA. However tPA does appear to bind saturably to the cells (or 
possibly to the matrix attached to them) with an estimated Kci in the range of 1 Q-9 
M. Using a similar approach, Bizik et al. (31) also showed binding of tPA to 
melanoma cells and found, interestingly, that the enzyme, when bound in this 
way, activated plasminogen efficiently in the presence of a2-macroglobulin. They 
suggested, without offering proof, that tPA might mediate invasion of melanoma 
cells in the manner suggested for uPA with other cell types. 
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APPENDIX 
PART A: METHODS 
A. 1 Cell culture 
Cells were cultured in a Hotpack CO2 incubator at 37°C in a humid 
atmosphere containing 5% CO2 in air. The culture medium used was RPMI 
1640 supplemented with 10% heat inactivated (S&C; 30 min) FCS, 50 
U/ml penicillin and 20 µg/ml streptomycin sulfate. All solutions used in the 
culture of cells were sterilized by filtration through a 0.45 µm Millipore filter. 
Cultures were passaged by incubating the cells briefly in 0.25% Trypsin, 
0.02% EDTA in TD (8.). Cell stocks were maintained in liquid nitrogen and 
prepared by controlled freezing in RP10 containing 10% DMSO. Cells were 
observed and photographed using a Nikon phase-contrast microscope 
with camera attachment. 
A.2 Mycoplasma staining 
All cell lines were tested for mycoplasma infection using Hoechst Stain no. 
33258 at a concentration of 0.5 µg/ml. 
A.3 Protease and inhibitor free (PIE) BSA 
Bovine serum albumin (Boehringer Mannheim) was dissolved in water to a 
concentration of 20 mg/ml. Acid labile protease inhibitors were removed 
by adjusting the solution to pH 3.0 with 0. 1 M HCI and standing at room 
temperature for 2 hours. The solution was then neutralized with 0.1 M 
NaOH and treated with diisopropylfluorphosphate (DFP) to inactivate 
serine proteases. The PIF BSA was stored in aliquots at -2QOC. 
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A.4 OFP treatment 
OFP treatment was used to remove protease activity by adding OFP to 1 O 
mM and incubating at 4QOC for 2 hours. Unreacted OFP was removed by 
dialysing extensively against O. 1 M Tris, pH 8. 1. 
A.5 BCA Protein determination 
Protein concentrations were determined using the Pierce Bicinchoninic 
acid reagent with BSA as a standard. The protocol was according to the 
directions supplied with the kit, however the amounts were scaled down for 
use in a 96 well microtiter plate. 
A.6 sos Polyacrylamide Gel Electrophoresis 
12°A> SOS polyacrylamide gels were prepared as follows: 
Running gel (15 ml}: 
12°A> acrylamide /bis-acrylamide (29: 1) 
1 x SOS running gel buffer (8.18) 
10µ1TEMEO 
50 µI 10% ammonium persulfate 
Stacking gel (5 ml}: 
4 % acrylamide /bis-acrylamide (29: 1) 
1 x SOS stacking gel buffer (B. 18} 
10µ1TEMEO 
50 µI 10% ammonium persulfate 
Samples were boiled for 5 min with a equal volume of 2x SOS sample 
buffer, loaded onto the gel and electrophoresed overnight at 80 V. 
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A. 7 Fibrin plate assay for plasminogen activator 
The assay relies on the measurement of plasminogen-dependent release 
of soluble, radioactive fibrin degradation peptides from an insoluble 
substrate of 1251-labelled fibrin adhering to the bottom surface of a plastic 
well. 
1251 fibrin coated 24 well plates (Corning) were prepared as described by 
Strickland and Beers (1976). 1251-Fibrinogen and cold fibrinogen were 
added to the wells, such that each well contained 120 000 to 130 000 cpm 
and 30 µg fibrinogen. The plates were dried at 3-,0c for 3 days and 
thereafter stored at room temperature. 
Before use the plates were incubated with 1 ml RPMI per well for 1 hour at 
37°c and the wells washed twice with PBS pH 7.4 and once with 0.1 M 
Tris.Cl, pH 8.1. 
For the assay, each well contained 2 µg of purified human plasminogen 
and 80 µg of PIF BSA in a final volume of 300 µI of 0.1 M Tris.Cl pH 8.1. 
Samples to be tested were added in a maximum of 40 µI. 
Control wells included: 
1. 300 µI trypsin (to give the total radioactivity present in each well. 
2. no sample (to detect background lysis due to plasmin contamination of 
the plasminogen). 
3. no sample, no plasminogen (to detect protease contamination of the 
other reagents) 
3. sample, no plasminogen (to detect plasminogen independent protease 
activity). 
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The standard wells contained 12 doubling dilutions of Urokinase diluted in 
the same medium as the samples. 
The plates were incubated at 37°C in a humid atmosphere and 50 µI 
aliquots were removed at 3 different timepoints and counted in a 1-counter. 
For each timepoint a standard curve was plotted and sample values falling 
on the linear part of the curve were determined and expressed as units of 
urokinase per ml. 
A.8 RNA Extraction 
RNA was extracted from cultured cells using the one-step guanidinium 
thiocyanate procedure*. Approximately 2 x 107 cells were trypsinized and 
washed twice with 10 ml PBS. Cell pellets were resuspended in 500 µI 
each of Solution D (4 M guanidinium thiocyanate, 25 mM sodium citrate pH 
7.0, 0.5% sarkosyl, 0.1 M P-mercaptoethanol). The following were added 
sequentially, mixing well after each addition: 50 µI sodium acetate, 500 µI 
water-saturated phenol and 100 µI chloroform:isoamyl alcohol (49:1). The 
solution was incubated on ice for 1 O min and then microfuged for 15 min. 
The aqueous phase was transferred to a fresh tube and the phenol 
extraction repeated. The aqueous phase was precipitated by addition of 
500 µI isopropanol and pelleted in a microfuge for 15 min. Each pellet was 
resuspended in 150 µI of Solution D and then precipitated with an equal 
volume of isopropanol as before. RNA pellets were rinsed with 70% 
ethanol, air-dried and taken up in DEPC treated water (8.6). RNA 
concentration was determined spectrophotometrically, assuming that 1 OD 
unit at 260 nm is equivalent to 40 µg of RNA. 2 x 107 cells yielded 
approximately 200 µg of total RNA. I obtained 260 nm/280 nm ratios in 
88 
excess of 1 .8. 
* Initially I had tried an alternative method which involves phenol extraction 
of the cytoplasmic fraction, however I consistently failed to obtain intact 
RNA using this procedure. Presumably the success of the Guanidinium 
method is due to lysis of the cells in the presence of this strong denaturant, 
thus immediately inactivating RNAses, whilst the lysis of cells with 
detergent may allow RNAse activity before addition of phenol. 
A.9 Formaldehyde gels 
1 % agarose gels containing 2.2 M formaldehyde were prepared as follows: 
1.5 g of MP agarose (Boehringer Mannheim) was melted in 108 ml DEPC 
treated water and held in a 600C water bath. 27 ml of 12.3 M deionized 
formaldehyde and 15 ml 1 Ox MOPS buffer were added and the mixture was 
poured into a slab mould. 20 µg of RNA was prepared for loading in each 
lane as follows: 
9 µI RNA (20 µg) 
20 µI deionized formamide 
7 µI deionized formaldehyde 
4 µI 10x MOPS 
Samples were heated at 55°C for 15 min and then 1 O µI RNA loading buffer 
was added. Gels were pre-electrophoresed in 1 x MOPS for 1 O min. 
Samples were then loaded and run overnight at 20 V (1 V /cm), 4°C. 
A. 1 o Northern hybridization analysis of RNA 
Formaldehyde was removed from RNA gels by washing in DEPC water for 
one hour (with six changes). They were then equilibrated in 20x SSC and 
capillary blotted overnight onto Hybond N membrane (Amersham). Blots 
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were dried, UV irradiated for two minutes and then stored at 4°C. Blots 
were rehydrated in 6x SSC and sealed in a plastic bag containing 10 ml 
RNA prehybridization fluid. After 2 hr at 42<>C in a shaking water bath, the 
prehybridization fluid was replaced and the freshly denatured, labelled 
probe was added at an activity of 106 cpm/ml. After hybridization 
overnight at 420C, blots were washed twice in 2x SSC, O. 1 % SOS for 15 
min at room temperature and then twice in 0.1 x SSC, 0. 1 % SOS for 15 min 
at 420C. Damp blots were sealed in plastic and autoradiographed at -so0c 
using preflashed Cronex 4 X-ray film and intensifying screens. Blots were 
stripped before reprobing by pouring boiling 0.1% SOS onto the blot and 
gently agitating until cold. Stripped blots were then prehybridized and 
hybridized as before. 
A.11.cDNA probe preparation 
Restriction enzyme digested plasmids were electrophoresed on 1 x 
TBE/1% low melting point agarose (Seaplaque) gels. The desired 
fragments were excised, weighed and diluted 1 :3 with water. 
Approximately 50 ng of the gel-purified fragment was random prime 
labelled (Boehringer Mannheim Random Prime Krt) using SO µCi 32P-dCTP 
(Amersham). A 1 ml Sephadex G-50 column was used to separate out 
unincorporated nucleotide. Fractions containing labelled DNA were pooled 
and an aliquot counted in a scintillation counter. Specific activities of at 
least 1 Q8 cpm/ µg were routinely obtained. 
A.12 Genomic DNA extraction 
Cultured cells were detached from dishes and washed once with PBS. The 
cells were centrifuged, resuspended in RSBT (8.10), incubated on ice for 
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15 min and then microfuged. The supernatant was removed and 
processed further for RNA extractions. The pellet containing nuclei was 
resuspended in 1% SDS, 1 mM EDTA, 1x SSC and 100 µg/ml proteinase K 
and incubated overnight at 50°c. Samples were phenol extracted and 
then precipitated by addition of 0. 1 volumes 3 M sodium acetate and 2 
volumes ethanol and pelleted by centrifugation in a microfuge. DNA pellets 
were rinsed with 70% ethanol, air-dried and resuspended in water. 
Concentration was determined spectrophotometrically, assuming that 1 
OD unit at 280 nm is equivalent to 50 µg of DNA. 
A.13 Southern Blot analysis of genomic DNA 
Genomic DNA was digested with EcoRI and Hindlll. 10 µg of digested 
DNA per lane together with a ).-Hindlll marker was electrophoresed on a 
1% agarosejTBE gel at 20 V overnight (1-2 V /cm). In order to facilitate 
sizing of bands later, gels were stained with 50 µg/ml of ethidium bromide 
and photographed. Gels were soaked in 0.2 M HCI for 1 O min, rinsed in 
water and then denatured with 0.5 M NaOH, 1.5 M NaCl for 90 min. After 
rinsing in water the gels were neutralized by soaking in 1.5 M NaCl, 1 M 
Tris.Cl pH 7.4 for 30 min. DNA was capillary blotted overnight onto 
Hybond N membrane (Amersham) using 20x SSC. Membranes were UV 
irradiated for 2 min and stored at 4°C. Blots were rinsed in 6x SSC and 
then prehybridized at 68°C for two hours. The prehybridization fluid was 
replaced with fresh solution containing denatured, labelled probe and 
hybridized with blots overnight at 68°C. Blots were washed twice in 2x 
SSC, 0.1 % SDS for 15 min at room temperature and then twice in 0.1 x 
SSC, 0.1% SDS for 15 min at 68°C. Damp membranes were sealed in 
91 
plastic and autoradiographed at -aooc using preflashed Cronex X-ray film 
and intensifying screens. 
A 14 Casein zymography 
Casein indicator gels contained 2°~ skim milk, 1.25% low melting agarose, 
0.04 M Tris.Cl, pH 8.1 and 50 µg/ml human plasminogen. 
lmmunochemical identification of PA type was achieved by adding 
inhibitory polyclonal antibodies to plasminogen activators (0.5 mg/ml). 
Plasminogen was omitted from the indicator gels in order to detect any 
plasminogen-independent lysis. Casein indicator gels were poured 
between glass plates with a backing of gelbond. SOS polyacrylamide gels 
containing fractionated PA samples were washed for 1 hr in 2.5% Triton-X 
100 to remove the SOS. The gels were then placed on the casein indicator 
gels and incubated in a humid environment at 37°C until bands of lysis 
were visible. Lytic bands were visualized on a dark ground light box and 
photographed. 
A 15 Antibody purification (94) 
20 ml of 0.06 M acetate buffer (pH 4.8) was added to 1 O ml of serum and 
the pH adjusted to 4.8 with HCI. Caprylic acid (Sigma C-2875) (0. 76 ml) 
was added dropwise with stirring and the stirring was continued for a 
further 30 min. The sample was centrifuged at 1 O 000 g for 30 min and the 
supernatant containing the antibody was dialyzed against 50 volumes of 
PBS containing 2 mM EOTA. lmmunoglobulins were precipitated by 
addition of an equal volume of saturated ammonium sulfate and stirring for 
30 min. The precipitate was pelleted by centrifugation, resuspended in 
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PBS and dialyzed against 250 volumes of PBS. The antibody 
concentration was determined using the BCA reagents (Pierce). 
A.16 Soft agar cloning 
UCT-Mel 3 cells were removed from semi-confluent dishes using trypsin, 
resuspended well in RP1 O and counted. All reagents and pipettes were 
held at 37oC prior to use. Feeder layers were prepared as follows: equal 
volumes of 1 % molten agar (Sigma, cell culture tested) and 2x RPMI were 
mixed with 0.5 volumes of FCS and 2 ml of the mixture pipetted into each 
35 mm dish. The final FCS concentration was 20%. Feeder layers were 
left to set at room temperature. Dilutions of cells were prepared at double 
the final concentration required and held at 37°C. For the cell layer, equal 
volumes of 1.32% agar and 2x RPMI were mixed with 0.5 volumes of FCS, 
and 0.5 ml of this was rapidly mixed with 0.5 ml of diluted cells and plated 
onto the feeder layer. The final FCS concentration in the cell layer was 
15%. 
Dishes were wrapped in saran wrap to prevent desiccation and incubated 
for approximately 14 days in a 37°C, 5% CO2 incubator. Clones were 
picked under a dissecting microscope using a capillary tube attached to a 
mouth pipette. Individual clones were expelled into wells of a 96 well tissue 
culture plate containing 50 µI of RP10, the plate wrapped in saran wrap and 
incubated as above. Clones were fed weekly, or when medium became 
yellow. When the wells became confluent, the cells were removed using 
versene and a plugged Pasteur pipette, centrifuged and plated in a 24 well 
plate. In a similar manner clones were transferred sequentially into 35 mm 
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and then multiple 60 mm dishes and frozen in RP10/10% DMSO at -80°C. 
A.17 Growth curves 
Cells were seeded in 35 mm tissue culture dishes (Corning) in 2 ml RP1 O at 
a density of 10s cells per dish. At timepoints of O (day after plating), 48, 120 
and 168 hours, duplicate dishes were trypsinized and counted on a Coulter 
counter. Remaining dishes were fed with 2 ml RP1 O. Doubling times were 
calculated from the slope of log cell number plotted against time. 
A.18 Conditioned medium 
Cells were seeded, in triplicate, in 60 mm tissue culture dishes (Corning) at 
densities of 1 x 10s, 2 x 10s and 10s. On the following day the medium was 
aspirated and the cell monolayer was washed twice with 5 ml serum free 
RPMI 1640. 2 ml of serum free RPMI 1640 was then added and the cells 
incubated for 24 hours. 
The conditioned medium was centrifuged at 1000 g for 5 min to pellet non-
adherent cells and then collected into a polyethylene tube containing PIF 
BSA at a final concentration of 400 µg/ml. Conditioned medium was stored 
frozen at -20°C. The adherent cells were trypsinized, pooled with the non-
adherent cell pellet and counted in the coulter counter. 
A. 19 lodogen tubes 
1 mg of lodogen (Pierce) was dissolved in 50 ml chloroform and 1 ml 
aliquots added to microfuge tubes. The chloroform was evaporated 
overnight at 4°C and the lodogen tubes stored at -80°C. 
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A.20 Iodination 
Proteins were iodinated using the Iodogen procedure. 10 µg of protein 
was incubated with a total equimolar amount of 1251 (50 µM) and Nat (50 
µM) in 50 µI of sodium phosphate buffer pH 7.4. Proportions of 1251 and Nal 
were varied depending on specific activity required. The reaction was 
allowed to proceed for 1 O min at room temperature and then terminated by 
removal from the Iodogen tube. The reaction was left at room temperature 
for a further 15 min and then applied to a 1 ml Sephadex G-50 column 
equilibrated with 0.05 M phosphate buffer containing 0.1% Triton X-100. 
Fractions (100 µI) were collected and counted in a gamma counter. 
Trichloroacetic acid (TCA) precipitable counts were determined by diluting 
1 µI of each fraction in 500 µI PBS/0.1% BSA and adding 50 µI of 100% 
TCA. After incubating on ice for 15 min the precipitate was microfuged for 
5 min. The % precipitable counts were (cpm in pellet/total cpm) x 100. 
A.21 Karyotyping 
A semiconfluent 60 mm dish of cells was harvested, resuspended in 5 ml of 
RPMI containing 0.2 µg/ml colcemid (Gibco) and incubated for 45 min in a 
37<>C, 5% CO2 incubator. Cells were then harvested and subjected to 
hypotonic treatment as follows: The aspirated cell pellet was tapped gently 
to resuspend cells, two drops of 0.56°~ KCI added, followed by 2 ml. Cells 
were gently resuspended and allowed to stand at room temperature for 20 
min. Cells were then centrifuged at 1500 rpm for 5 min and the 
supernatant removed. The cell pellet was tapped gently and 2 ml fixative 
(methanol:acetic acid, 3:1) added. Cells were pelleted and resuspended in 
fixative as before, and allowed to stand for 20 min before pelleting again. 
All but 0.5 ml of the fixative was removed, and the pellet resuspended. 
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Cells were dropped from a height of 30 cm onto clean, cooled slides. 
Slides were flamed dry and stained with Giemsa stain for 10 min followed 
by washing in water. Slides were viewed under 100x magnification. 
A.22 Plasmid purification 
Alkaline lysis (136): 
A 200 ml culture of bacteria carrying plasmid was grown up overnight in TB 
containing 100 µg/ml of ampicillin. The bacteria were harvested by 
centrifugation at 8000 rpm in a Beckman JA-10 rotor. The pellet was 
resuspended in 18 ml of solution I (8.15), followed by addition of 2 ml 
freshly prepared 2 mg/ml lysozyme. 40 ml of freshly prepared solution II 
(8.16) was added, mixed by inversion and left to stand for 5 min. Ice-cold 
solution Ill (8.17) (20 ml) was added and mixed thoroughly by shaking the 
centrifuge bottle. The solution containing a flocculant white precipitate was 
left on ice for 1 O min. The precipitate was pelleted by centrifugation at 1 O 
000 rpm and the supernatant filtered through a syringe containing glass 
wool, in order to remove remaining precipitate. Plasmid was precipitated 
by addition of 0.6 volumes of isopropanol. The pellet was rinsed with 70% 
ethanol, air-dried and then resuspended in 3 ml of TE. 
CsCI purification 
The pellet obtained after alkaline lysis was made up to 4 ml with TE, 4 g of 
CsCI added followed by 0.4 ml of 1 O mg/ml ethidium bromide. The 
solution was transferred to a 5 ml Beckman Quikseal tube which was 
balanced and then sealed. Tubes were centrifuged in a Beckman LB-80 
ultracentrifuge for 18 hours at 50 000 rpm, 2CJOC. The fluorescent plasmid 
band was removed through the side of the tube using a syringe and 
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needle. Ethidium bromide was removed by repeated extraction with 
isoamyl alcohol, until the aqueous phase was no longer pink. The solution 
was diluted threefold with water and then ethanol precipitated. The pellet 
was rinsed with 70% ethanol, air dried and resuspended in TE. Plasmid 
DNA concentration was determined spectrophotometrically. 
* CsCI purification was used only when very pure plasmid DNA was 
required, as in the case of transfections. 
A.23 Boiling minipreps 
1.5 ml of an overnight culture was pelleted by microcentrifugation for 20 
sec. The supernatant was discarded and the bacterial pellet thoroughly 
resuspended in 300 µI of STET buffer (8.14} containing 200 µg lysozyme. 
Tubes were then held on ice for 5 min before placing in a boiling water bath 
for 1 min. The combination of heating and detergent causes lysis of cell 
walls and release of bacterial RNA and plasmid DNA. Microcentrifugation 
for 15 min pellets debris and chromosomal DNA, producing a loose 
gummy pellet. The supernatant, containing plasmid DNA was removed 
and precipitated by addition of an equal volume of isopropanol. After 
centrifugation the supernatant was removed, the pellet rinsed with 70% 
ethanol and air dried. Plasmid DNA was resupended in 50 µI of TE. RNAse 
at 40 µg/ml was added to restriction enzyme digests. 
A.24 Establishment of UCT-Mel 3 (100} 
History: Tumor tissue was obtained from a 71 year old Caucasian female 
(DH). A pigmented lesion was removed from the medial aspect of the left 
calf of this patient in January 1976 and was found to be a malignant 
melanoma. Recurrence in the periphery of the scar occurred 8 months 
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later. In April 1977, a liver scan indicated possible metastasis and in March 
1978 a large melanomatous deposit was removed from the left lobe, from 
which the cell line in tissue culture was established. Malignant infiltration 
subsequently occurred in the sternum, lungs, spine and brain and the 
patient died in December, 1978. 
The liver metastasis obtained for tissue culture was very soft and fragile 
with large pale nodules of tumor visible in the reddish black liver tissue. 
The tumour tissue disintegrated readily upon mincing with scissors and 
large numbers of viable cells were obtained from the trypsin digested 
tissue. The initial culture dishes were passaged after 48 hr. After five 
weekly passages normal fibroblasts contamination of the culture had 
increased markedly and fibroblasts threatened to overgrow the tumor cells. 
This line, however, shed large numbers of viable cells into the medium and 
these were collected from a number of dishes, centrifuged, and reseeded 
on a separate dish. In this manner a relatively pure culture of melanoma 
cells was obtained. This procedure was repeated twice before a pure 
culture of melanoma cells was established. The cells removed from the 
supernatant adhered readily when plated on a new petri dish. 
The UCT-Mel 3 cell line grew as an adherent monolayer of triangular 
dendritic cells. At confluence the cells piled up, forming large multilayered 
clumps and therefore failed to display contact inhibition. Giant 
multinucleated cells were frequently seen. The cells were nonpigmented at 
both high and low densities. 
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A.25 CAT assay 
Cells were washed once in PBS and then in TEN (8.) buffer and transferred 
to a 1.5 ml microfuge tube. The cell pellet was resuspended in 60 µI of 0.25 
M Tris, pH 8.0 and cells disrupted by three freeze/thaw cycles. Cell debris 
was pelleted in a microfuge and the supernatant stored at -8()0C. The 
standard reaction mix was as follows: 
5 µI Acetyl CoA 
5 µI C14-Chloramphenicol 
x µI sample/standard dilution of CAT 
(125-x) µI 0.1 M TrisCI, pH 8.0 
Commercial CAT enzyme was diluted in 0.1 M Tris, pH 8.0 to 0.1, 0.05, 
0.025, 0.01 and 0.005 units for the standard curve. Negative controls were 
cell lysates from untransfected cells. Samples were incubated at 37°C for 
0.5-20 hr. Cell debris was pelleted and the supernatant extracted with 300 
µI of xylene. The upper xylene phase was transferred to a fresh tube and 
back extracted with 100 µI of Tris buffer. The extraction was repeated for 
maximum sensitivity. 200 µI of the xylene was transferred to a scintillation 
vial containing lnstagel and counted in a P-counter. Values obtained for 
cell lysates were calculated from the standard curve. 
A.26 PCR 
PCR reaction mix (50 µI total): 
1 x PCR buffer 
200 µM dNTP's 
0.2 µM primers 
2.0 mM MgCl2 
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1.25 U Taq polymerase 
Reaction mix was overlaid with mineral oil 
A.27 Cell lysates for PCR 
Cultured cells were resuspended at a concentration of 106 cells/ml in PCR 
lysis buffer. Samples were then incubated at seoc for 1-2 hr and then 
heated to 95oC for 10 min. Cell lysates were stored at-SOOC and 1-2 µI 
used as template in a 50 µI PCR reaction. 
A.28 Ligations 
Ligations were performed using 100 ng of vector DNA and a 2: 1 molar ratio 
of insert to vector. The reaction volume was 10 µI, containing 1 u of ligase 
(Boehringer Mannheim) and the buffer supplied by the manufacturer. The 
ligation proceeded overnight in a 1 &>C waterbath. 
A.29 Transformation 
Competent DH5 E.Coli cells were prepared using the calcium chloride 
method. 20 µI of competent cells were incubated with the following for 20 
min on ice: 
1. 1 ng of intact vector (to assess transformation efficiency of 
competent cells) 
2. 5 µI of the ligation reaction. 
3. 50 ng of digested vector (to assess efficiency of digestion). 
4. 50 ng of digested and Cf Ped vector (to assess efficiency of CIP). 
5. 5 µI water (negative control). 
The transformations were heat shocked for 90 sec at 42oC after which 800 
µI of LB was added and the tubes shaken for 1 hour at 37oC in order to 
100 
allow expression of ampicillin resistance. Various dilutions of the 
transformations were plated on LB agar containing 100 µg/ml Ampicillin 
and incubated overnight at 37°C. 
The completed digest was incubated with 5 u of CIP for 60 min at 37°C. 
The CIP was heat inactivated at 75°C for 15 min and removed by 
phenol/chloroform extraction. The DNA was ethanol precipitated 
A.30 Chromogenic assay 
A microtiter plate was coated overnight at 4°C with polyclonal a-tPA (#123) 
diluted to 20 µg/ml in PBS. The plate was then blocked with 200 µI/well of 
5% skim milk powder dissolved in PBS, for 1 hr at room temperature. After 
rinsing twice with PBS, 50 µI of either standard samples (diluted in RPMI 
containing 0.1% Tween 20) or conditioned medium was added for 1 hr. 
Unbound antigen was removed by washing 7x with TST. The detection 
solution contained 20 µg/ml plasminogen and 5 mM PL-substrate 
(Spectrozyme) in 0.1 M Tris (pH 7.4)/ 0.1% Tween 20. 100 µI/well of 
detection solution was added and the plate was incubated, with shaking at 
37°c. The optical density was read at 405 nm at different timepoints (60, 
90 and 120 min). 
A.31 Transcription 
DNA templates were linearized, gel-purified and phenol extracted before 
use. Transcription reaction mixes (20 µI) were prepared as follows (using 
the Promega kit): 
4 µI 1 Ox transcription buffer 
2 µ1100 mM OTT 
1 µI RNAsin (50 u) 
101 
4 µI NTP's (0.5 mM) 
2 µI 3H-UTP (24 µM) 
1 µI template ( ± 1 µg) 
1 µI SP6/T7 RNA polymerase 
Transcription was at 37°C (17) or 400C (SP6) for 1 hr. Samples were then 
phenol extracted, precipitated with ethanol and electrophoresed on a 4% 
denaturing polyacrylamide gel. 
A.32 Acid treatment of cells 
Receptors were stripped of ligand before performing all binding 
experiments. The cells were detached with versene, washed once in 
binding medium (HEPES buffered RPMI containing 0.5% BSA) and then 
resuspended in 2 ml of 50 mM glycine (pH 3), 0.1 M NaCl for 3 min at RT. 
The acid was neutralized by addition of0.5 ml of 0.5 M HEPES (pH 7.7), 
0.1 M NaCl. Binding buffer was then added to a volume of 1 O ml and the 
cells were pelleted by centrifugation. 
PART B: SOLUTIONS 
B.1 PBS 
137 mM NaCl 
2.7 mM KCI 
4.3 mM Na2HP04 
1.4 mM KH2P04 
B.2 MOPS 
0.1 M MOPS (3-(N-morpholino)propanesulfonic acid) 
102 
40 mM sodium acetate 
5 mM EDTA (pH 8.0) 
8.3 10xT8E 
89 mM Tris base 
89 mM boric acid 
2 mM EDTA, pH 8.0 
8.4 Solution D 
4 M guanidinium thiocyanate 
25 mM sodium citrate pH 7 
0.5% sarkosyl 
0.1 M P-mercaptoethanol 
8.5 Deionised formamide/formaldehyde 
Deionised formamide/formaldehyde was prepared by tumbling overnight 
with 1% (w/v) mixed bed resin (8iorad AG-501 XS), followed by filtration 
through Whatman No.1. 
8.6 DEPC treatment 
DEPC was added to solutions at 0.1 %, incubated overnight (37°C), then 
autoclaved to remove remaining DEPC. 
8.7 20x SSC 
3M NaCl 
0.3 M Naacitrate, pH 7.0 
8.8 RNA hybridization solution 
6xSSC 
50% deionised formamide 
5x Denhardts solution 
0.5%SDS 
100 µg/ml salmon sperm DNA (freshly denatured) 
103 
B.9 DNA hybridization solution 
6xSSC 
8.10 
8.11 
8.12 
B.13 
8.14 
5x Denhardts solution 
0.5%SDS 
100 µg/ml salmon sperm DNA (freshly denatured) 
RSBT 
10 mM Tris.Cl (pH 7.5) 
10mM NaCl 
1.5 mM MgCl2 
2% Triton X-100 
RNA loading buffer 
50% glycerol 
1 mM EDTA (pH 8.0) 
0.25% bromophenol blue 
0.25% xylene cyanol FF 
LB medium 
10 g bacto-tryptone 
5 g bacto-yeast extract 
10 g NaCl 
TE 
10 mM Tris.Cl (pH 8.0) 
1 mM EDTA 
STET 
0.1 M NaCl 
10 mM Tris.Cl (pH 8.0) 
1 mM EDTA 
5% Triton-X 100 
104 
B.15 Solution I 
50 mM glucose 
25 mM Tris.Cl (pH 8.0) 
10 mM EDTA 
8.16 Solution II (freshly prepared) 
0.2 N NaOH 
1%SDS 
s. 17 Solution Ill 
60 ml of 5 M potassium acetate 
11.5 ml glacial acetic acid 
28.5 ml Hi> 
8.18 SDS PAGE Buffers 
4x running gel buffer: 
1.5 M Tris.Cl (pH 8.8), 0.4% SDS 
4x stacking gel buffer: 
0.5 M Tris.Cl (pH 6.8), 0.4% SDS 
5x electrophoresis buffer: 
0.125 M Tris.Cl (pH 8.5) 
0.96 M Glycine 
0.5%SDS 
2x SDS sample buffer: 
1x stacking buffer, 20% glycerol, 4% SDS, 0.001% Bromophenol blue. 
8.19 PCR lysis buffer 
50mM KCI 
10 mM Tris.Cl (pH 8.3) 
2.SmM MgCl2 
0.5% Nonidet P-40 
105 
106 
0.5% Triton-X 100 
120 µg/ml proteinase K 
8.20 (5x) Versene 
3.5 mM Nci2EDTA 
13.4mM KCI 
0.685 M Nci2HP04.2Hil 
7.4 mM KH2P04 
8.21 TEN 
50 mM Tris.Cl (pH 7.5) 
100 mM NaCl 
5mM EDTA 
8.22 (1 OOx) Denhardts solution 
2% Ficoll 400 
2% polyvinylpyrrolidine 
2%8SA 
8.23 (2x) trypsin diluent (TD) 
0.27 M NaCl 
0.01 M KCI 
1.4 mM Nci2HPQ4 
0.05 M Tris (pH 7.4) 
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